TW202403401A - Contact lens product - Google Patents
Contact lens product Download PDFInfo
- Publication number
- TW202403401A TW202403401A TW112138175A TW112138175A TW202403401A TW 202403401 A TW202403401 A TW 202403401A TW 112138175 A TW112138175 A TW 112138175A TW 112138175 A TW112138175 A TW 112138175A TW 202403401 A TW202403401 A TW 202403401A
- Authority
- TW
- Taiwan
- Prior art keywords
- contact lens
- multifocal contact
- diopter
- annular
- area
- Prior art date
Links
- 239000007853 buffer solution Substances 0.000 claims abstract description 17
- 239000000017 hydrogel Substances 0.000 claims description 54
- 239000000203 mixture Substances 0.000 claims description 45
- 239000000463 material Substances 0.000 claims description 26
- 229920001296 polysiloxane Polymers 0.000 claims description 26
- 239000000634 cycloplegic agent Substances 0.000 claims description 10
- 229940124570 cycloplegic agent Drugs 0.000 claims description 10
- IGCJKJTYHIDZJN-UHFFFAOYSA-N (4-phenyldiazenylphenyl) 2-methylprop-2-enoate Chemical group C1=CC(OC(=O)C(=C)C)=CC=C1N=NC1=CC=CC=C1 IGCJKJTYHIDZJN-UHFFFAOYSA-N 0.000 claims description 2
- 210000001650 focal adhesion Anatomy 0.000 claims 1
- 230000004379 myopia Effects 0.000 abstract description 34
- 208000001491 myopia Diseases 0.000 abstract description 34
- 210000000695 crystalline len Anatomy 0.000 description 215
- 230000000052 comparative effect Effects 0.000 description 47
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 45
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 35
- XMLYCEVDHLAQEL-UHFFFAOYSA-N 2-hydroxy-2-methyl-1-phenylpropan-1-one Chemical compound CC(C)(O)C(=O)C1=CC=CC=C1 XMLYCEVDHLAQEL-UHFFFAOYSA-N 0.000 description 27
- 238000010586 diagram Methods 0.000 description 26
- -1 2-(4-benzoyl-3-hydroxyphenoxy)ethyl Chemical group 0.000 description 25
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 24
- 230000000903 blocking effect Effects 0.000 description 24
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 23
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Substances CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 23
- 235000011187 glycerol Nutrition 0.000 description 19
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 18
- 238000002834 transmittance Methods 0.000 description 15
- 229940088644 n,n-dimethylacrylamide Drugs 0.000 description 13
- YLGYACDQVQQZSW-UHFFFAOYSA-N n,n-dimethylprop-2-enamide Chemical compound CN(C)C(=O)C=C YLGYACDQVQQZSW-UHFFFAOYSA-N 0.000 description 13
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- OKKRPWIIYQTPQF-UHFFFAOYSA-N Trimethylolpropane trimethacrylate Chemical compound CC(=C)C(=O)OCC(CC)(COC(=O)C(C)=C)COC(=O)C(C)=C OKKRPWIIYQTPQF-UHFFFAOYSA-N 0.000 description 11
- 210000005252 bulbus oculi Anatomy 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 206010057430 Retinal injury Diseases 0.000 description 8
- NMMXJQKTXREVGN-UHFFFAOYSA-N 2-(4-benzoyl-3-hydroxyphenoxy)ethyl prop-2-enoate Chemical compound OC1=CC(OCCOC(=O)C=C)=CC=C1C(=O)C1=CC=CC=C1 NMMXJQKTXREVGN-UHFFFAOYSA-N 0.000 description 7
- VCYCUECVHJJFIQ-UHFFFAOYSA-N 2-[3-(benzotriazol-2-yl)-4-hydroxyphenyl]ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCC1=CC=C(O)C(N2N=C3C=CC=CC3=N2)=C1 VCYCUECVHJJFIQ-UHFFFAOYSA-N 0.000 description 7
- BESKSSIEODQWBP-UHFFFAOYSA-N 3-tris(trimethylsilyloxy)silylpropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCC[Si](O[Si](C)(C)C)(O[Si](C)(C)C)O[Si](C)(C)C BESKSSIEODQWBP-UHFFFAOYSA-N 0.000 description 7
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 7
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 6
- 238000004364 calculation method Methods 0.000 description 6
- 239000003292 glue Substances 0.000 description 6
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 6
- 210000001525 retina Anatomy 0.000 description 6
- 229910000077 silane Inorganic materials 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000001508 eye Anatomy 0.000 description 5
- 230000004436 pseudomyopia Effects 0.000 description 5
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 4
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 4
- 210000004087 cornea Anatomy 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 239000004205 dimethyl polysiloxane Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000000416 hydrocolloid Substances 0.000 description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- QSAVEGSLJISCDF-UHFFFAOYSA-N 2-hydroxy-2-phenylacetic acid (1,2,2,6-tetramethyl-4-piperidinyl) ester Chemical compound C1C(C)(C)N(C)C(C)CC1OC(=O)C(O)C1=CC=CC=C1 QSAVEGSLJISCDF-UHFFFAOYSA-N 0.000 description 3
- 229930003347 Atropine Natural products 0.000 description 3
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 3
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 3
- 239000003637 basic solution Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000004402 high myopia Effects 0.000 description 3
- 229920000831 ionic polymer Polymers 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000002637 mydriatic agent Substances 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000004515 progressive myopia Effects 0.000 description 3
- 210000001747 pupil Anatomy 0.000 description 3
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 2
- WMANZASCYVPFIX-UHFFFAOYSA-N C(C(=C)C)(=O)OCCOC(C(=C)C)=O.OC1=C(C=C(C=C1)CCOC(C(=C)C)=O)N1N=C2C(=N1)C=CC=C2 Chemical compound C(C(=C)C)(=O)OCCOC(C(=C)C)=O.OC1=C(C=C(C=C1)CCOC(C(=C)C)=O)N1N=C2C(=N1)C=CC=C2 WMANZASCYVPFIX-UHFFFAOYSA-N 0.000 description 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 2
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 2
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 2
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 2
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229960000396 atropine Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000001886 ciliary effect Effects 0.000 description 2
- SKYSRIRYMSLOIN-UHFFFAOYSA-N cyclopentolate Chemical compound C1CCCC1(O)C(C(=O)OCCN(C)C)C1=CC=CC=C1 SKYSRIRYMSLOIN-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229950002420 eucatropine Drugs 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960002646 scopolamine Drugs 0.000 description 2
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- LLLWMXQKXWIRDZ-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one Chemical compound C=CN1CCCC1=O.C=CN1CCCC1=O LLLWMXQKXWIRDZ-UHFFFAOYSA-N 0.000 description 1
- MMWFQFGXFPTUIF-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one 2-hydroxyethyl 2-methylprop-2-enoate 2-(2-methylprop-2-enoyloxy)ethyl 2-methylprop-2-enoate prop-2-enyl 2-methylprop-2-enoate Chemical compound C=CN1CCCC1=O.CC(=C)C(=O)OCCO.CC(=C)C(=O)OCC=C.CC(=C)C(=O)OCCOC(=O)C(C)=C MMWFQFGXFPTUIF-UHFFFAOYSA-N 0.000 description 1
- NXBDLTJZZIKTKL-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one 2-hydroxyethyl 2-methylprop-2-enoate 2-methylprop-2-enoic acid 2-(2-methylprop-2-enoyloxy)ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(O)=O.C=CN1CCCC1=O.CC(=C)C(=O)OCCO.CC(=C)C(=O)OCCOC(=O)C(C)=C NXBDLTJZZIKTKL-UHFFFAOYSA-N 0.000 description 1
- QRIMLDXJAPZHJE-UHFFFAOYSA-N 2,3-dihydroxypropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(O)CO QRIMLDXJAPZHJE-UHFFFAOYSA-N 0.000 description 1
- ZEERWUUHFUFJJT-UHFFFAOYSA-N 2-hydroxy-2-methyl-1-phenylpropan-1-one Chemical compound CC(C)(O)C(=O)C1=CC=CC=C1.CC(C)(O)C(=O)C1=CC=CC=C1 ZEERWUUHFUFJJT-UHFFFAOYSA-N 0.000 description 1
- KKOWZRLUUCIGQY-UHFFFAOYSA-N 2-hydroxyethyl 2-methylprop-2-enoate 2-methylprop-2-enoic acid 2-(2-methylprop-2-enoyloxy)ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(O)=O.CC(=C)C(=O)OCCO.CC(=C)C(=O)OCCOC(=O)C(C)=C KKOWZRLUUCIGQY-UHFFFAOYSA-N 0.000 description 1
- LNGIIXGLYTUUHJ-UHFFFAOYSA-N 2-methylbut-2-enoic acid methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CC=C(C)C(O)=O LNGIIXGLYTUUHJ-UHFFFAOYSA-N 0.000 description 1
- ILZXXGLGJZQLTR-UHFFFAOYSA-N 2-phenylethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCC1=CC=CC=C1 ILZXXGLGJZQLTR-UHFFFAOYSA-N 0.000 description 1
- HPSGLFKWHYAKSF-UHFFFAOYSA-N 2-phenylethyl prop-2-enoate Chemical compound C=CC(=O)OCCC1=CC=CC=C1 HPSGLFKWHYAKSF-UHFFFAOYSA-N 0.000 description 1
- UURVHRGPGCBHIC-UHFFFAOYSA-N 3-(ethenoxycarbonylamino)propanoic acid 4-[[[[[[[[[[[[[[[[[[[[[[[[[[[4-ethenoxycarbonyloxybutyl(dimethyl)silyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]butyl ethenyl carbonate 1-ethenylpyrrolidin-2-one ethenyl N-[3-tris(trimethylsilyloxy)silylpropyl]carbamate Chemical compound C=CN1CCCC1=O.OC(=O)CCNC(=O)OC=C.C[Si](C)(C)O[Si](CCCNC(=O)OC=C)(O[Si](C)(C)C)O[Si](C)(C)C.C[Si](C)(CCCCOC(=O)OC=C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)CCCCOC(=O)OC=C UURVHRGPGCBHIC-UHFFFAOYSA-N 0.000 description 1
- ZOPSJJCUEOEROC-NSQCPRBHSA-N 3-[[butyl(dimethyl)silyl]oxy-dimethylsilyl]propyl 2-methylprop-2-enoate;n,n-dimethylprop-2-enamide;1-ethenylpyrrolidin-2-one;2-hydroxyethyl 2-methylprop-2-enoate;[(2r)-2-hydroxy-3-[3-[methyl-bis(trimethylsilyloxy)silyl]propoxy]propyl] 2-methylprop-2-enoat Chemical compound CN(C)C(=O)C=C.C=CN1CCCC1=O.CC(=C)C(=O)OCCO.CC(=C)C(=O)OCCOC(=O)C(C)=C.CCCC[Si](C)(C)O[Si](C)(C)CCCOC(=O)C(C)=C.CC(=C)C(=O)OC[C@H](O)COCCC[Si](C)(O[Si](C)(C)C)O[Si](C)(C)C ZOPSJJCUEOEROC-NSQCPRBHSA-N 0.000 description 1
- GRMQEBHYNZUEPL-UHFFFAOYSA-N C(C(=C)C)(=O)OC1=CC(=C(C(=O)C2=CC=CC=C2)C=C1)O.C(C(=C)C)(=O)OC1=CC(=C(C(=O)C2=CC=CC=C2)C=C1)O Chemical compound C(C(=C)C)(=O)OC1=CC(=C(C(=O)C2=CC=CC=C2)C=C1)O.C(C(=C)C)(=O)OC1=CC(=C(C(=O)C2=CC=CC=C2)C=C1)O GRMQEBHYNZUEPL-UHFFFAOYSA-N 0.000 description 1
- FMAGWDPYWGGAFM-UHFFFAOYSA-N C(C(=C)C)(=O)OCCOC(C(=C)C)=O.C(C=C)(=O)OCCOC1=CC(=C(C=C1)C(C1=CC=CC=C1)=O)O Chemical compound C(C(=C)C)(=O)OCCOC(C(=C)C)=O.C(C=C)(=O)OCCOC1=CC(=C(C=C1)C(C1=CC=CC=C1)=O)O FMAGWDPYWGGAFM-UHFFFAOYSA-N 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- ZTVIKZXZYLEVOL-MCOXGKPRSA-N Homatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(O)C1=CC=CC=C1 ZTVIKZXZYLEVOL-MCOXGKPRSA-N 0.000 description 1
- 206010020675 Hypermetropia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 229920001616 Polymacon Polymers 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 1
- 230000004329 axial myopia Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- ZBMWDBPPKFTVJF-UHFFFAOYSA-N butane-1,1,1-triol 2-methylprop-2-enoic acid Chemical compound C(C(=C)C)(=O)O.C(C(=C)C)(=O)O.C(C(=C)C)(=O)O.OC(CCC)(O)O ZBMWDBPPKFTVJF-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960001815 cyclopentolate Drugs 0.000 description 1
- 230000003500 cycloplegic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- KLTPDYHAASMFGP-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO.CCCCCCO KLTPDYHAASMFGP-UHFFFAOYSA-N 0.000 description 1
- 229960000857 homatropine Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000004305 hyperopia Effects 0.000 description 1
- 201000006318 hyperopia Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000012634 optical imaging Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000004331 refractive myopia Effects 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- NLAIHECABDOZBR-UHFFFAOYSA-M sodium 2,2-bis(2-methylprop-2-enoyloxymethyl)butyl 2-methylprop-2-enoate 2-hydroxyethyl 2-methylprop-2-enoate 2-methylprop-2-enoate Chemical compound [Na+].CC(=C)C([O-])=O.CC(=C)C(=O)OCCO.CCC(COC(=O)C(C)=C)(COC(=O)C(C)=C)COC(=O)C(C)=C NLAIHECABDOZBR-UHFFFAOYSA-M 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
Images
Landscapes
- Eyeglasses (AREA)
- Control And Other Processes For Unpacking Of Materials (AREA)
Abstract
Description
本發明是有關於一種隱形眼鏡產品,且特別是有關於一種可以預防近視或控制近視進展的隱形眼鏡產品。The present invention relates to a contact lens product, and in particular to a contact lens product that can prevent myopia or control the progression of myopia.
根據世界衛生組織(WHO)資料顯示世界各國近視盛行率介於8%至62%之間,然而在臺灣的調查發現18歲以下青少年與兒童的近視率高達85%,其近視發生的比率明顯超越其他國家,其中原因很可能是由於近年來高度發展的3C電子裝置,使幼童的眼睛過早接受不當刺激與造成用眼過度,目前研究顯示,一但幼童罹患早發性近視,其後會以一定的速度增加近視度數,研究另指出,得到近視的年齡越低,日後演變成高度近視(大於等於6.0 D)的機率越高,而高度近視患者更可能引發視網膜剝離、青光眼等嚴重的併發症。因此,倘若能夠於察覺幼童患有假性近視時即進行控制與減緩近視,則可有效避免假性近視轉變為近視,進而預防高度近視的發生。According to data from the World Health Organization (WHO), the prevalence of myopia in various countries around the world ranges from 8% to 62%. However, a survey in Taiwan found that the myopia rate among adolescents and children under the age of 18 is as high as 85%, and the rate of myopia is significantly higher than In other countries, the reason is probably due to the highly developed 3C electronic devices in recent years, which expose young children’s eyes to premature stimulation and excessive eye use. Current research shows that once young children suffer from early-onset myopia, they will later develop myopia. Myopia will increase at a certain rate. Research also points out that the younger the age at which myopia occurs, the higher the chance of developing high myopia (greater than or equal to 6.0 D) in the future, and patients with high myopia are more likely to develop severe myopia such as retinal detachment and glaucoma. Complications. Therefore, if myopia can be controlled and slowed down as soon as it is discovered that a young child has pseudomyopia, it can effectively prevent pseudomyopia from turning into myopia, thereby preventing the occurrence of high myopia.
近視的主要成因是眼球光學構造的變異所造成,其中形成光學成像主要藉由眼球的角膜、水晶體與眼球長度等因子所影響,正常人的眼睛可以將影像正確聚焦於視網膜上而得到清晰的影像,近視患者則可能由於角膜與水晶體的屈光度過強(屈光性近視)或是眼球軸距過長(軸性近視)而導致影像聚焦於視網膜之前,呈現影像模糊的近視症狀。幼兒童的近視症狀可分為近視與假性近視,其中近視是屬於眼球軸距過長的情形,無法藉由矯正而恢復,但若為假性近視,則為睫狀肌過度用力的短暫近視症狀,屬於可矯正的近視症狀。臨床上有許多用於矯正兒童假性近視的方式,主要有角膜塑型鏡與長效型散瞳劑等方式,但其中的角膜塑型鏡易造成高度外部壓力而使配戴者產生不適感,而一般單獨使用長效型散瞳劑須要較高濃度的劑量方能發揮矯正近視的效用,但也相對提高產生藥物副作用的機率。The main cause of myopia is the variation of the optical structure of the eyeball. The formation of optical imaging is mainly affected by factors such as the cornea, crystalline lens, and length of the eyeball. Normal people's eyes can correctly focus the image on the retina to obtain a clear image. Myopia patients may suffer from myopia symptoms in which the image is focused in front of the retina due to the excessive refractive power of the cornea and crystalline lens (refractive myopia) or the excessively long axial distance of the eyeball (axial myopia). Myopia symptoms in young children can be divided into myopia and pseudomyopia. Myopia is a condition in which the axial distance of the eyeball is too long and cannot be restored through correction. However, pseudomyopia is a short-term myopia caused by excessive exertion of the ciliary muscles. Symptoms are correctable symptoms of myopia. Clinically, there are many ways to correct pseudomyopia in children, mainly including orthokeratology lenses and long-acting mydriatic agents. However, the orthokeratology lenses can easily cause high external pressure and cause discomfort to the wearer. , and long-acting mydriatic agents generally require a higher concentration of doses to correct myopia when used alone, but this also increases the probability of drug side effects.
本發明之一目的是提供一種隱形眼鏡產品,其包含多焦點隱形眼鏡及緩衝溶液,且多焦點隱形眼鏡浸泡於緩衝溶液中。藉此,多焦點隱形眼鏡可提供物理性的矯正,從而可有效預防近視或控制近視進展,且可避免配戴不適感並可降低藥物副作用產生的機率。One object of the present invention is to provide a contact lens product, which includes a multifocal contact lens and a buffer solution, and the multifocal contact lens is soaked in the buffer solution. In this way, multifocal contact lenses can provide physical correction, which can effectively prevent myopia or control the progression of myopia, avoid wearing discomfort and reduce the probability of drug side effects.
依據本發明提供一種隱形眼鏡產品,包含多焦點隱形眼鏡與緩衝溶液。多焦點隱形眼鏡包含中心區及至少二環形區。至少二環形區分別為一第一環形區以及一第二環形區,中心區、第二環形區與第一環形區由中心至周邊依序相連且同圓心,其中第二環形區的屈光度與中心區的屈光度不同,第一環形區的屈光度與中心區的屈光度不同。多焦點隱形眼鏡浸泡於緩衝溶液中。多焦點隱形眼鏡的中心區的屈光度為PowC,多焦點隱形眼鏡的第一環形區的最大屈光度為PowP1,多焦點隱形眼鏡的中心區的直徑為DiC,多焦點隱形眼鏡的第一環形區的外圓直徑為DiP1,多焦點隱形眼鏡的第二環形區的外圓直徑為DiP2,其滿足下列條件: 2 D < |PowC–PowP1|; 0.15 ≤ DiC/DiP1 ≤ 1;以及 0.2 ≤ DiC/DiP2 ≤ 1。 According to the present invention, a contact lens product is provided, which includes a multifocal contact lens and a buffer solution. Multifocal contact lenses include a central zone and at least two annular zones. At least two annular areas are a first annular area and a second annular area respectively. The central area, the second annular area and the first annular area are sequentially connected from the center to the periphery and are concentric. The diopter of the second annular area is The refractive power of the first annular zone is different from the refractive power of the central zone. Multifocal contact lenses are soaked in buffer solution. The refractive power of the central zone of the multifocal contact lens is PowC, the maximum refractive power of the first annular zone of the multifocal contact lens is PowP1, the diameter of the central zone of the multifocal contact lens is DiC, and the first annular zone of the multifocal contact lens is DiC. The outer diameter of the multifocal contact lens is DiP1, and the outer diameter of the second annular zone of the multifocal contact lens is DiP2, which meets the following conditions: 2 D < |PowC–PowP1|; 0.15 ≤ DiC/DiP1 ≤ 1; and 0.2 ≤ DiC/DiP2 ≤ 1.
請參照第1圖,其係繪示依照本發明一實施方式的一種隱形眼鏡產品100的示意圖,隱形眼鏡產品100包含多焦點隱形眼鏡110與緩衝溶液120,多焦點隱形眼鏡110浸泡於緩衝溶液120中。Please refer to Figure 1, which is a schematic diagram of a
請併同參照第2圖,其係繪示第1圖中多焦點隱形眼鏡110的平面示意圖。多焦點隱形眼鏡110包含中心區111以及第一環形區112,第一環形區112同心環繞中心區111,第一環形區112的屈光度與中心區111的屈光度不同,藉此,可賦予多焦點隱形眼鏡110多焦點的功能,使周邊的影像能夠聚焦於視網膜之前,從而有效減緩眼球的軸距增長,避免近視的惡化。依據本發明一實施例,中心區111的屈光度固定。Please also refer to Figure 2, which is a schematic plan view of the
多焦點隱形眼鏡110的中心區111與第一環形區112至少一者為非球面,藉此,有助於第一環形區112設計為具有梯度漸變的屈光度。At least one of the
請復參照第1圖,緩衝溶液120包含睫狀肌麻痺劑,睫狀肌麻痺劑於緩衝溶液120中的重量百分比濃度為ConA,其滿足下列條件:0 < ConA ≤ 1%。藉此,睫狀肌麻痺劑的濃度適當,有助於放鬆睫狀肌並可降低藥物副作用產生的機率。或者,其可滿足下列條件:0 < ConA ≤ 0.5%。又或者,其可滿足下列條件:0 < ConA ≤ 0.25%。再或者,其可滿足下列條件:0 < ConA ≤ 0.1%。更或者,其可滿足下列條件:0 < ConA ≤ 0.05%。甚或者,其可滿足下列條件:0 < ConA ≤ 0.01%。前述緩衝溶液120的製備方式,可先配製一基礎溶液,基礎溶液的配方可為市面上用於浸泡、保存隱形眼鏡的溶液,再於基礎溶液中添加睫狀肌麻痺劑至所需的濃度,此外,基礎溶液與睫狀肌麻痺劑之間不會產生化學反應。Please refer to Figure 1 again. The
依據前述之隱形眼鏡產品100,製備多焦點隱形眼鏡110的組成物可包含藍光吸收成分。藉此,多焦點隱形眼鏡110可吸收高能量藍光,進而可降低視網膜受藍光傷害的機率。依據本發明一實施例,藍光吸收成分可為四苯基二甲基丙烯酸(4-(phenyldiazenyl) phenyl methacrylate)。According to the aforementioned
依據前述之隱形眼鏡產品100,製備多焦點隱形眼鏡110的組成物可包含UV(Ultraviolet)吸收成分,UV吸收成分可為但不限於2-[3-(2H-苯并***-2-基)-4-羥基苯基]乙基2-甲基丙烯酸(2-[3-(2H-Benzotriazol-2-yl)-4-hydroxyphenyl]ethyl methacrylate)、2-丙烯酸 2-(4-苯甲醯-3-羥基苯氧基)乙基酯(2-(4-benzoyl-3-hydroxyphenoxy)ethyl acrylate)、4-甲基丙烯醯氧基-2-羥基二苯甲酮(4-methacryloxy-2-hydroxybenzophenone)、2-苯基乙基丙烯酸酯(2-Phenylethyl acrylate)、2-甲基丙烯酸苯乙烯酯(2-Phenylethyl methacrylate)、2-[2-羥基-5-[2-(甲基丙烯醯氧)乙基]苯基]-2H-苯并***(2-(2'-Hydroxy-5'-Methacryloxyethylphenyl)-2H-Benzotriazole)或2-丙烯酸 2-(4-苯甲醯-3-羥基苯氧基)乙基酯(2-(4-Benzoyl-3-Hydroxyphenoxy) Ethyl Acrylate)。藉此,多焦點隱形眼鏡110可吸收高能量UV光,進而可降低視網膜受UV光傷害的機率。依據本發明一實施例,UV吸收成分為2-[2-羥基-5-[2-(甲基丙烯醯氧)乙基]苯基]-2H-苯并***,依據本發明另一實施例,UV吸收成分為2-丙烯酸 2-(4-苯甲醯-3-羥基苯氧基)乙基酯。前述UV吸收成分可同時使用或單獨使用。According to the aforementioned
依據前述之隱形眼鏡產品100,多焦點隱形眼鏡110的材質可為矽水膠(Silicone Hydrogel),藉此,可有效提高多焦點隱形眼鏡110的透氧率,可避免角膜因缺氧而產生紅眼、血絲、紅腫等現象,以提供長時間配戴的舒適感。前述矽水膠可為但不限於經美國食品藥物管理局(USFDA)歸類至第5群組的隱形眼鏡材料,如Balafilcon A、Comfilcon A、Efrofilcon A、Enfilcon A、Galyfilcon A、Lotrafilcon A、Lotrafilcon B、Narafilcon A、Narafilcon B、Senofilcon A、Delefilcon A、Somofilcon A等材料。According to the aforementioned
製備前述矽水膠的組成物可包含甲基丙烯酸羥乙酯(2-Hydroxyethyl Methacrylate)、甲基丙烯醯氧丙基三(三甲基矽氧烷基)矽烷(3-Methacryloyloxypropyltris(Trimethylsilyloxy) Silane)、2-羥基-2-甲基-1-苯基-1-丙酮(2-Hydroxy-2-Methyl-Propiophenone)、N-乙烯基-2-吡咯酮(N-Vinyl-2-Pyrrolidinone)、N,N-二甲基丙烯醯胺(N,N-Dimethyl Acrylamide)、二甲基丙烯酸乙二醇酯(Ethylene Glycol Dimethacrylate)、(3-甲基丙烯醯氧基-2-羥基丙氧基)丙基双(三甲基矽氧基)甲基(3-(3-Methacryloxy-2-Hydroxypropoxy)Propylbis(Trimethylsiloxy)Methylsilane)、異丙醇(Isopropyl Alcohol)以及甲基丙烯酸(Methacrylic Acid)。The composition for preparing the aforementioned silicone hydrogel may include 2-Hydroxyethyl Methacrylate and 3-Methacryloyloxypropyltris(Trimethylsilyloxy) Silane. , 2-Hydroxy-2-Methyl-1-phenyl-1-propanone (2-Hydroxy-2-Methyl-Propiophenone), N-Vinyl-2-Pyrrolidinone (N-Vinyl-2-Pyrrolidinone), N ,N,N-Dimethyl Acrylamide, Ethylene Glycol Dimethacrylate, (3-methacryloxy-2-hydroxypropoxy)propyl Propylbis(Trimethylsiloxy)Methylsilane), Isopropyl Alcohol and Methacrylic Acid.
較佳地,矽水膠的組成物中各成分的重量百分比如下:甲基丙烯酸羥乙酯為0.05%~25%、甲基丙烯醯氧丙基三(三甲基矽氧烷基)矽烷為0.1%~40%、2-羥基-2-甲基-1-苯基-1-丙酮為0.01%~5%、N-乙烯基-2-吡咯酮為0.1%~35%、N,N-二甲基丙烯醯胺為0.1%~40%、二甲基丙烯酸乙二醇酯為0.01%~5%、(3-甲基丙烯醯氧基-2-羥基丙氧基)丙基双(三甲基矽氧基)甲基為0.1%~30%、異丙醇為0.1%~30%以及甲基丙烯酸為0.01%~5%。Preferably, the weight percentage of each component in the silicone hydrogel composition is as follows: hydroxyethyl methacrylate is 0.05% to 25%, and methacryloxypropyltris(trimethylsiloxane)silane is 0.1%~40%, 2-hydroxy-2-methyl-1-phenyl-1-propanone is 0.01%~5%, N-vinyl-2-pyrrolidone is 0.1%~35%, N,N- Dimethylacrylamide is 0.1%~40%, ethylene glycol dimethacrylate is 0.01%~5%, (3-methacryloxy-2-hydroxypropoxy)propyl bis(tris) Methylsiloxy)methyl is 0.1%~30%, isopropyl alcohol is 0.1%~30%, and methacrylic acid is 0.01%~5%.
更佳地,矽水膠的組成物中各成分的重量百分比如下:甲基丙烯酸羥乙酯為0.1%~10%、甲基丙烯醯氧丙基三(三甲基矽氧烷基)矽烷為1%~40%、2-羥基-2-甲基-1-苯基-1-丙酮為0.1%~2%、N-乙烯基-2-吡咯酮為1%~35%、N,N-二甲基丙烯醯胺為1%~20%、二甲基丙烯酸乙二醇酯為0.1%~2%、(3-甲基丙烯醯氧基-2-羥基丙氧基)丙基双(三甲基矽氧基)甲基為1%~30%、異丙醇為1%~20%以及甲基丙烯酸為0.1%~2%。More preferably, the weight percentage of each component in the silicone hydrogel composition is as follows: hydroxyethyl methacrylate is 0.1% to 10%, and methacryloxypropyltris(trimethylsiloxane)silane is 1%~40%, 2-hydroxy-2-methyl-1-phenyl-1-propanone is 0.1%~2%, N-vinyl-2-pyrrolidone is 1%~35%, N,N- Dimethylacrylamide is 1%~20%, ethylene glycol dimethacrylate is 0.1%~2%, (3-methacryloxy-2-hydroxypropoxy)propyl bis(tris) Methylsiloxy)methyl is 1%~30%, isopropyl alcohol is 1%~20%, and methacrylic acid is 0.1%~2%.
製備前述矽水膠的組成物可包含甲基丙烯酸羥乙酯、甲基丙烯醯氧丙基三(三甲基矽氧烷基)矽烷、2-羥基-2-甲基-1-苯基-1-丙酮、N-乙烯基-2-吡咯酮、N,N-二甲基丙烯醯胺、二甲基丙烯酸乙二醇酯、3-乙醯氧基-2-羥基丙氧基丙基封端的聚二甲基矽氧烷((3-Acryloxy-2-Hydroxypropoxypropyl) Terminated Polydimethylsiloxane)以及正己醇(1-Hexanol)。The composition for preparing the aforementioned silicone hydrogel may include hydroxyethyl methacrylate, methacryloyloxypropyl tris(trimethylsiloxy)silane, 2-hydroxy-2-methyl-1-phenyl- 1-Propane, N-vinyl-2-pyrrolidone, N,N-dimethylacrylamide, ethylene glycol dimethacrylate, 3-acetyloxy-2-hydroxypropoxypropyl Terminated Polydimethylsiloxane ((3-Acryloxy-2-Hydroxypropoxypropyl) Terminated Polydimethylsiloxane) and n-hexanol (1-Hexanol).
較佳地,矽水膠的組成物中各成分的重量百分比如下:甲基丙烯酸羥乙酯為0.05%~25%、甲基丙烯醯氧丙基三(三甲基矽氧烷基)矽烷為0.1%~40%、2-羥基-2-甲基-1-苯基-1-丙酮為0.01%~5%、N-乙烯基-2-吡咯酮為0.1%~35%、N,N-二甲基丙烯醯胺為0.1%~40%、二甲基丙烯酸乙二醇酯為0.01%~5%、3-乙醯氧基-2-羥基丙氧基丙基封端的聚二甲基矽氧烷為0.1%~40%以及正己醇為0.1%~30%。Preferably, the weight percentage of each component in the silicone hydrogel composition is as follows: hydroxyethyl methacrylate is 0.05% to 25%, and methacryloxypropyltris(trimethylsiloxane)silane is 0.1%~40%, 2-hydroxy-2-methyl-1-phenyl-1-propanone is 0.01%~5%, N-vinyl-2-pyrrolidone is 0.1%~35%, N,N- Dimethylacrylamide is 0.1%~40%, ethylene glycol dimethacrylate is 0.01%~5%, 3-acetyloxy-2-hydroxypropoxypropyl-terminated polydimethylsilica Oxane is 0.1%~40% and n-hexanol is 0.1%~30%.
更佳地,矽水膠的組成物中各成分的重量百分比如下:甲基丙烯酸羥乙酯為0.1%~10%、甲基丙烯醯氧丙基三(三甲基矽氧烷基)矽烷為1%~40%、2-羥基-2-甲基-1-苯基-1-丙酮為0.1%~2%、N-乙烯基-2-吡咯酮為1%~35%、N,N-二甲基丙烯醯胺為1%~20%、二甲基丙烯酸乙二醇酯為0.1%~2%、3-乙醯氧基-2-羥基丙氧基丙基封端的聚二甲基矽氧烷為1%~40%以及正己醇為1%~30%。More preferably, the weight percentage of each component in the silicone hydrogel composition is as follows: hydroxyethyl methacrylate is 0.1% to 10%, and methacryloxypropyltris(trimethylsiloxane)silane is 1%~40%, 2-hydroxy-2-methyl-1-phenyl-1-propanone is 0.1%~2%, N-vinyl-2-pyrrolidone is 1%~35%, N,N- Dimethylacrylamide is 1%~20%, ethylene glycol dimethacrylate is 0.1%~2%, 3-acetyloxy-2-hydroxypropoxypropyl-terminated polydimethylsilica Oxane is 1%~40% and n-hexanol is 1%~30%.
製備前述矽水膠的組成物可包含甲基丙烯酸羥乙酯、甲基丙烯醯氧丙基三(三甲基矽氧烷基)矽烷、2-羥基-2-甲基-1-苯基-1-丙酮、N-乙烯基-2-吡咯酮、N,N-二甲基丙烯醯胺、二甲基矽氧烷改性氨酯寡聚體(Polysiloxane Macromer)、甲基丙烯酸甲酯(Methyl Methacrylate)以及乙醇(Ethanol)。The composition for preparing the aforementioned silicone hydrogel may include hydroxyethyl methacrylate, methacryloyloxypropyl tris(trimethylsiloxy)silane, 2-hydroxy-2-methyl-1-phenyl- 1-Propane, N-vinyl-2-pyrrolidone, N,N-dimethylacrylamide, dimethylsiloxane modified urethane oligomer (Polysiloxane Macromer), methyl methacrylate (Methyl Methacrylate) and ethanol (Ethanol).
較佳地,矽水膠的組成物中各成分的重量百分比如下:甲基丙烯酸羥乙酯為0.05%~25%、甲基丙烯醯氧丙基三(三甲基矽氧烷基)矽烷為0.1%~40%、2-羥基-2-甲基-1-苯基-1-丙酮為0.01%~5%、N-乙烯基-2-吡咯酮為0.1%~35%、N,N-二甲基丙烯醯胺為0.1%~40%、二甲基矽氧烷改性氨酯寡聚體為0.1%~40%、甲基丙烯酸甲酯為0.1%~20%以及乙醇為0.1%~30%。Preferably, the weight percentage of each component in the silicone hydrogel composition is as follows: hydroxyethyl methacrylate is 0.05% to 25%, and methacryloxypropyltris(trimethylsiloxane)silane is 0.1%~40%, 2-hydroxy-2-methyl-1-phenyl-1-propanone is 0.01%~5%, N-vinyl-2-pyrrolidone is 0.1%~35%, N,N- Dimethylacrylamide is 0.1%~40%, dimethylsiloxane modified urethane oligomer is 0.1%~40%, methyl methacrylate is 0.1%~20%, and ethanol is 0.1%~ 30%.
更佳地,矽水膠的組成物中各成分的重量百分比如下:甲基丙烯酸羥乙酯為0.1%~10%、甲基丙烯醯氧丙基三(三甲基矽氧烷基)矽烷為1%~40%、2-羥基-2-甲基-1-苯基-1-丙酮為0.1%~2%、N-乙烯基-2-吡咯酮為1%~35%、N,N-二甲基丙烯醯胺為1%~20%、二甲基矽氧烷改性氨酯寡聚體為1%~40%、甲基丙烯酸甲酯為1%~10%以及乙醇為1%~20%。More preferably, the weight percentage of each component in the silicone hydrogel composition is as follows: hydroxyethyl methacrylate is 0.1% to 10%, and methacryloxypropyltris(trimethylsiloxane)silane is 1%~40%, 2-hydroxy-2-methyl-1-phenyl-1-propanone is 0.1%~2%, N-vinyl-2-pyrrolidone is 1%~35%, N,N- Dimethylacrylamide is 1%~20%, dimethylsiloxane modified urethane oligomer is 1%~40%, methyl methacrylate is 1%~10%, and ethanol is 1%~ 20%.
依據本發明一實施例,前述矽水膠的組成物可更包含藍光吸收成分或UV吸收成分,較佳地,前述矽水膠的組成物中藍光吸收成分或UV吸收成分的重量百分比為0.01%~10%,更佳地,前述矽水膠的組成物中藍光吸收成分或UV吸收成分的重量百分比為0.1%~5%。According to an embodiment of the present invention, the aforementioned silicone hydrogel composition may further include a blue light absorbing component or a UV absorbing component. Preferably, the weight percentage of the blue light absorbing component or UV absorbing component in the aforementioned silicone hydrogel composition is 0.01%. ~10%, more preferably, the weight percentage of blue light absorbing components or UV absorbing components in the aforementioned silicone hydrogel composition is 0.1% ~ 5%.
藉由調整前述矽水膠中各成分的比例,可有效增加多焦點隱形眼鏡110的透氧率與硬度,此外,前述矽水膠的組成物可依實際需要添加其他成分。By adjusting the proportion of each component in the silicone hydrogel, the oxygen permeability and hardness of the
依據前述之隱形眼鏡產品100,多焦點隱形眼鏡110的材質可為水膠(Hydrogel),藉此,可維持多焦點隱形眼鏡110的濕潤、滑順與柔軟舒適的水潤感,能夠長時間配戴,避免配戴時的異物感。前述水膠可為經美國食品藥物管理局歸類至第一群組的隱形眼鏡材料,即低含水量(小於50重量百分比)的非離子型聚合物(nonionic polymer),例如名稱為Helfilcon A&B、Hioxifilcon B、Mafilcon 、Polymacon、Tefilcon、Tetrafilcon A等材料。或者,前述水膠可為經美國食品藥物管理局歸類至第二群組的隱形眼鏡材料,即高含水量(大於50重量百分比)的非離子型聚合物,例如名稱為Acofilcon A、Alfafilcon A、Hilafilcon B、Hioxifilcon A、Hioxifilcon B、Hioxifilcon D、Nelfilcon A、Nesofilcon A、Omafilcon A以及Samfilcon A等材料。或者,前述水膠可為經美國食品藥物管理局歸類至第三群組的隱形眼鏡材料,即低含水量(小於50重量百分比)的離子型聚合物(ionic polymer),例如名稱為Deltafilcon A等材料。或者,前述水膠可為經美國食品藥物管理局核准的第四群組的隱形眼鏡材料、即高含水量(大於50重量百分比)的離子型聚合物,例如名稱為Etafilcon A、Focofilcon A、Methafilcon A、Methafilcon B 、Ocufilcon A、Ocufilcon B、Ocufilcon C、Ocufilcon D、Ocufilcon E、Phemfilcon A、Vifilcon A等材料。According to the aforementioned
製備前述水膠的組成物可包含甲基丙烯酸羥乙酯、二甲基丙烯酸乙二醇酯、2-羥基-2-甲基-1-苯基-1-丙酮、甘油(Glycerol)、三羥甲基丙烷三甲基丙烯酸酯(1,1,1-Trimethylol Propane Trimethacrylate)以及甲基丙烯酸。The composition for preparing the aforementioned hydrogel may include hydroxyethyl methacrylate, ethylene glycol dimethacrylate, 2-hydroxy-2-methyl-1-phenyl-1-propanone, glycerol (Glycerol), trihydroxy Methylpropane trimethacrylate (1,1,1-Trimethylol Propane Trimethacrylate) and methacrylic acid.
較佳地,前述水膠的組成物中各成分的重量百分比如下:甲基丙烯酸羥乙酯為10%~96%、二甲基丙烯酸乙二醇酯為0.01%~5%、2-羥基-2-甲基-1-苯基-1-丙酮為0.01%~5%、甘油為0.1%~30%、三羥甲基丙烷三甲基丙烯酸酯為0.01%~5%以及甲基丙烯酸為0.01%~5%。Preferably, the weight percentage of each component in the aforementioned water glue composition is as follows: hydroxyethyl methacrylate is 10% to 96%, ethylene glycol dimethacrylate is 0.01% to 5%, 2-hydroxy- 2-Methyl-1-phenyl-1-propanone is 0.01%~5%, glycerol is 0.1%~30%, trimethylolpropane trimethacrylate is 0.01%~5%, and methacrylic acid is 0.01 %~5%.
更佳地,前述水膠的組成物中各成分的重量百分比如下:甲基丙烯酸羥乙酯為40%~96%、二甲基丙烯酸乙二醇酯為0.1%~2%、2-羥基-2-甲基-1-苯基-1-丙酮為0.1%~2%、甘油為0.1%~20%、三羥甲基丙烷三甲基丙烯酸酯為0.1%~2%以及甲基丙烯酸為0.1%~2%。More preferably, the weight percentage of each component in the aforementioned water glue composition is as follows: hydroxyethyl methacrylate is 40% ~ 96%, ethylene glycol dimethacrylate is 0.1% ~ 2%, 2-hydroxy- 2-Methyl-1-phenyl-1-propanone is 0.1%~2%, glycerin is 0.1%~20%, trimethylolpropane trimethacrylate is 0.1%~2%, and methacrylic acid is 0.1 %~2%.
製備前述水膠的組成物可包含甲基丙烯酸羥乙酯、二甲基丙烯酸乙二醇酯、2-羥基-2-甲基-1-苯基-1-丙酮、甘油、三羥甲基丙烷三甲基丙烯酸酯以及2-甲基-2-丙烯酸-2,3-二羥基丙酯(Glycerol Monomethacrylate)。The composition for preparing the aforementioned hydrogel may include hydroxyethyl methacrylate, ethylene glycol dimethacrylate, 2-hydroxy-2-methyl-1-phenyl-1-propanone, glycerol, and trimethylolpropane. Trimethacrylate and 2-methyl-2-acrylic acid-2,3-dihydroxypropyl ester (Glycerol Monomethacrylate).
較佳地,前述水膠的組成物中各成分的重量百分比如下:甲基丙烯酸羥乙酯為10%~94.87%、二甲基丙烯酸乙二醇酯為0.01%~5%、2-羥基-2-甲基-1-苯基-1-丙酮為0.01%~5%、甘油為0.1%~30%、三羥甲基丙烷三甲基丙烯酸酯為0.01%~5%以及2-甲基-2-丙烯酸-2,3-二羥基丙酯為5%~60%。Preferably, the weight percentage of each component in the aforementioned water glue composition is as follows: hydroxyethyl methacrylate is 10% to 94.87%, ethylene glycol dimethacrylate is 0.01% to 5%, 2-hydroxy- 2-Methyl-1-phenyl-1-propanone is 0.01%~5%, glycerin is 0.1%~30%, trimethylolpropane trimethacrylate is 0.01%~5%, and 2-methyl- 2-Acrylic acid-2,3-dihydroxypropyl ester is 5%~60%.
更佳地,前述水膠的組成物中各成分的重量百分比如下:甲基丙烯酸羥乙酯為40%~79.6%、二甲基丙烯酸乙二醇酯為0.1%~2%、2-羥基-2-甲基-1-苯基-1-丙酮為0.1%~2%、甘油為0.1%~20%、三羥甲基丙烷三甲基丙烯酸酯為0.1%~2%以及2-甲基-2-丙烯酸-2,3-二羥基丙酯為20%~50%。More preferably, the weight percentage of each component in the aforementioned water glue composition is as follows: hydroxyethyl methacrylate is 40% ~ 79.6%, ethylene glycol dimethacrylate is 0.1% ~ 2%, 2-hydroxy- 2-Methyl-1-phenyl-1-propanone is 0.1%~2%, glycerol is 0.1%~20%, trimethylolpropane trimethacrylate is 0.1%~2%, and 2-methyl- 2-Acrylic acid-2,3-dihydroxypropyl ester is 20%~50%.
製備前述水膠的組成物可包含甲基丙烯酸羥乙酯、二甲基丙烯酸乙二醇酯、2-羥基-2-甲基-1-苯基-1-丙酮、甘油以及N-乙烯基-2-吡咯酮。The composition for preparing the aforementioned hydrogel may include hydroxyethyl methacrylate, ethylene glycol dimethacrylate, 2-hydroxy-2-methyl-1-phenyl-1-propanone, glycerol and N-vinyl- 2-pyrrolidone.
較佳地,前述水膠的組成物中各成分的重量百分比如下:甲基丙烯酸羥乙酯為10%~96%、二甲基丙烯酸乙二醇酯為0.01%~5%、2-羥基-2-甲基-1-苯基-1-丙酮為0.01%~5%、甘油為0.1%~30%以及N-乙烯基-2-吡咯酮為0.1%~25%。Preferably, the weight percentage of each component in the aforementioned water glue composition is as follows: hydroxyethyl methacrylate is 10% to 96%, ethylene glycol dimethacrylate is 0.01% to 5%, 2-hydroxy- 2-Methyl-1-phenyl-1-propanone is 0.01%~5%, glycerol is 0.1%~30%, and N-vinyl-2-pyrrolidone is 0.1%~25%.
更佳地,前述水膠的組成物中各成分的重量百分比如下:甲基丙烯酸羥乙酯為40%~96%、二甲基丙烯酸乙二醇酯為0.1%~2%、2-羥基-2-甲基-1-苯基-1-丙酮為0.1%~2%、甘油為1%~20%以及N-乙烯基-2-吡咯酮為0.1%~10%。More preferably, the weight percentage of each component in the aforementioned water glue composition is as follows: hydroxyethyl methacrylate is 40% ~ 96%, ethylene glycol dimethacrylate is 0.1% ~ 2%, 2-hydroxy- 2-Methyl-1-phenyl-1-propanone is 0.1%~2%, glycerin is 1%~20%, and N-vinyl-2-pyrrolidone is 0.1%~10%.
依據本發明一實施例,前述水膠的組成物可更包含藍光吸收成分或UV吸收成分,較佳地,前述水膠的組成物中藍光吸收成分或UV吸收成分的重量百分比為0.01%~10%,更佳地,前述水膠的組成物中藍光吸收成分或UV吸收成分的重量百分比為0.1%~5%。According to an embodiment of the present invention, the aforementioned hydrogel composition may further include a blue light absorbing component or a UV absorbing component. Preferably, the weight percentage of the blue light absorbing component or UV absorbing component in the aforementioned hydrogel composition is 0.01%~10 %, more preferably, the weight percentage of blue light absorbing components or UV absorbing components in the aforementioned hydrogel composition is 0.1% to 5%.
藉由調整前述水膠中各成分的比例,可有效增加多焦點隱形眼鏡110的含水量與軟度,此外,前述水膠的組成物可依實際需要添加其他成分。水膠組成物與矽水膠組成物中使用的單體,如甲基丙烯酸羥乙酯、甲基丙烯酸、2-甲基-2-丙烯酸-2,3-二羥基丙酯、N-乙烯基-2-吡咯酮、甲基丙烯醯氧丙基三(三甲基矽氧烷基)矽烷、N,N-二甲基丙烯醯胺、(3-甲基丙烯醯氧基-2-羥基丙氧基)丙基双(三甲基矽氧基)甲基、3-乙醯氧基-2-羥基丙氧基丙基封端的聚二甲基矽氧烷、甲基丙烯酸甲酯等,亦可視實際需要互相替換。By adjusting the proportion of each component in the hydrogel, the water content and softness of the
請復參照第2圖,多焦點隱形眼鏡110的中心區111的直徑為DiC,其可滿足下列條件:4 mm ≤ DiC ≤ 10 mm。藉此,可依照不同生理狀態下的瞳孔大小彈性調整,提升中心區111矯正近視的精確度,使影像能夠完整清晰呈現於視網膜上。較佳地,其可滿足下列條件:5 mm ≤ DiC ≤ 9 mm。Please refer to Figure 2 again. The diameter of the
多焦點隱形眼鏡110的第一環形區112的外圓直徑為DiP1,其可滿足下列條件:6 mm ≤ DiP1 ≤ 17 mm。藉此,可依照眼裂大小彈性調整,以提供多焦點隱形眼鏡110適當的服貼感,增加多焦點隱形眼鏡110於配戴後的穩定度。較佳地,其可滿足下列條件:7 mm ≤ DiP1 ≤ 15 mm。The outer diameter of the first
多焦點隱形眼鏡110的中心區111的直徑為DiC,多焦點隱形眼鏡110的第一環形區112的外圓直徑為DiP1,其可滿足下列條件:0.15 ≤ DiC/DiP1 < 1。藉此,DiC/DiP1的大小適當,有利於依照個人眼球生理狀況而設計適當的多焦點隱形眼鏡110,進而有利於矯正近視。The diameter of the
多焦點隱形眼鏡110的中心區111的屈光度為PowC,其可滿足下列條件:-6.00 ≤ PowC ≤ -0.25。藉此,可依照使用者需求,提供適當的矯正近視度數,進而提供清晰的影像。The diopter of the
多焦點隱形眼鏡110的第一環形區112的最大屈光度為PowP1,其可滿足下列條件:-5.50 ≤ PowP1 ≤ -0.50。藉此,可適當設計第一環形區112的最大屈光度,有利於矯正近視。The maximum refractive power of the first
多焦點隱形眼鏡110的中心區111的屈光度為PowC,多焦點隱形眼鏡110的第一環形區112的最大屈光度為PowP1,其可滿足下列條件:|PowC – PowP1| ≤ 3。藉此,有利於矯正近視,減緩第一環形區112的屈光度增加幅度,避免因最大屈光度增幅過大所造成不適感。或者,其可滿足下列條件:|PowC – PowP1| ≤ 2。又或者,其可滿足下列條件:|PowC – PowP1| ≤ 1.5。再或者,其可滿足下列條件:|PowC – PowP1| ≤ 1。更或者,其可滿足下列條件:|PowC – PowP1| ≤ 0.5。甚或者,其可滿足下列條件:|PowC – PowP1| ≤ 0.25。The refractive power of the
請參照第3圖,其係繪示依照本發明另一實施方式的一種多焦點隱形眼鏡210的平面示意圖。多焦點隱形眼鏡210包含中心區211、第一環形區212以及第二環形區213,中心區211、第二環形區213、第一環形區212由中心至周邊依序相連且同圓心,中心區211的直徑為DiC,第一環形區212的外圓直徑為DiP1,第二環形區213的外圓直徑為DiP2,其中,第二環形區213的屈光度與中心區211的屈光度不同,第一環形區212的屈光度與中心區211的屈光度不同。藉此,可賦予多焦點隱形眼鏡210多焦點的功能,使周邊的影像能夠聚焦於視網膜之前,從而有效減緩眼球的軸距增長,避免近視的惡化。依據本發明一實施例,中心區211的屈光度固定。Please refer to FIG. 3 , which is a schematic plan view of a
中心區211、第一環形區212與第二環形區213中至少一者可為非球面,藉此,有助於第一環形區212及/或第二環形區213設計為具有梯度漸變的屈光度。At least one of the
多焦點隱形眼鏡210的第二環形區213的外圓直徑為DiP2,其可滿足下列條件:5 mm ≤ DiP2 ≤ 13 mm。藉此,可有效緩和屈光度的提升幅度。較佳地,其可滿足下列條件:6 mm ≤ DiP2 ≤ 12 mm。The outer diameter of the second
多焦點隱形眼鏡210的中心區211的直徑為DiC,多焦點隱形眼鏡210的第二環形區213的外圓直徑為DiP2,其可滿足下列條件:0.2 ≤ DiC/DiP2 < 1。藉此,可有效減緩第二環形區213的屈光度的增幅,減少因屈光度增幅過大所造成的不適感。The diameter of the
關於多焦點隱形眼鏡210的其他性質可與多焦點隱形眼鏡110相同,在此將不再予以贅述。Other properties of the
請參照第4圖,其係繪示依照本發明又一實施方式的一種多焦點隱形眼鏡310的平面示意圖,多焦點隱形眼鏡310包含中心區311、第一環形區312、第二環形區313以及第三環形區314,中心區311、第三環形區314、第二環形區313、第一環形區312由中心至周邊依序相連且同圓心,中心區311的直徑為DiC,第一環形區312的外圓直徑為DiP1,第二環形區313的外圓直徑為DiP2,第三環形區314的外圓直徑為DiP3,其中第三環形區314的屈光度與中心區311的屈光度不同,第二環形區313的屈光度與中心區311的屈光度不同,第一環形區312的屈光度與中心區311的屈光度不同。藉此,可賦予多焦點隱形眼鏡310多焦點的功能,使周邊的影像能夠聚焦於視網膜之前,從而有效減緩眼球的軸距增長,避免近視的惡化。依據本發明一實施例,中心區311的屈光度固定。Please refer to Figure 4, which is a schematic plan view of a multifocal contact lens 310 according to another embodiment of the present invention. The multifocal contact lens 310 includes a central area 311, a first annular area 312, and a second annular area 313. And the third annular area 314, the central area 311, the third annular area 314, the second annular area 313, and the first annular area 312 are connected in order from the center to the periphery and are concentric. The diameter of the central area 311 is DiC, and the first annular area 311 has a diameter of DiC. The outer diameter of the annular area 312 is DiP1, the outer diameter of the second annular area 313 is DiP2, and the outer diameter of the third annular area 314 is DiP3, where the refractive power of the third annular area 314 is different from the refractive power of the central area 311 , the refractive power of the second annular area 313 is different from the refractive power of the central area 311, and the refractive power of the first annular area 312 is different from the refractive power of the central area 311. In this way, the multifocal contact lens 310 can be given a multifocal function, so that peripheral images can be focused in front of the retina, thereby effectively slowing down the growth of the eyeball's axial distance and avoiding the worsening of myopia. According to an embodiment of the present invention, the diopter of the central area 311 is fixed.
由第2圖至第4圖可知,依據本發明的多焦點隱形眼鏡可於中心區(111、211、311)外同心環設至少一個環形區(第一環形區(112、212、312)、第二環形區(213、313)、第三環形區(314)),環形區的數量以及其屈光度的配置可彈性調整以符合個人眼球生理狀況,從而能提升矯正近視的效果,而能有效預防近視或控制近視進展。As can be seen from Figures 2 to 4, the multifocal contact lens according to the present invention can be provided with at least one annular area (first annular area (112, 212, 312) concentrically outside the central area (111, 211, 311) , the second annular area (213, 313), the third annular area (314)), the number of annular areas and the configuration of their diopters can be flexibly adjusted to suit the physiological conditions of the individual eyeballs, thereby improving the effect of correcting myopia and effectively Prevent myopia or control myopia progression.
依據本發明另提供一種隱形眼鏡產品,包含多焦點隱形眼鏡,其中製備多焦點隱形眼鏡的組成物包含藍光吸收成分。藉此,多焦點隱形眼鏡可吸收高能量藍光,進而可降低視網膜受藍光傷害的機率。關於藍光吸收成分、多焦點隱形眼鏡的材質以及多焦點隱形眼鏡的其他細節可參照上述關於第1圖至第4圖的內容,在此將不再予以贅述。According to the present invention, another contact lens product is provided, including a multifocal contact lens, wherein the composition for preparing the multifocal contact lens includes a blue light absorbing component. In this way, multifocal contact lenses can absorb high-energy blue light, thereby reducing the chance of retinal damage from blue light. Regarding the blue light absorbing components, the material of the multifocal contact lens and other details of the multifocal contact lens, please refer to the above-mentioned content in Figures 1 to 4, and will not be repeated here.
<第一實施例><First Embodiment>
第一實施例的多焦點隱形眼鏡,包含中心區以及第一環形區,第一環形區同心環繞中心區,中心區以及第一環形區中至少一者為非球面,關於第一實施例多焦點隱形眼鏡的結構可參照第2圖。The multifocal contact lens of the first embodiment includes a central area and a first annular area, the first annular area concentrically surrounds the central area, and at least one of the central area and the first annular area is aspherical. Regarding the first embodiment For an example of the structure of a multifocal contact lens, please refer to Figure 2.
第一實施例的多焦點隱形眼鏡中,中心區的直徑為DiC,第一環形區的外圓直徑為DiP1,中心區的屈光度為PowC,第一環形區的最大屈光度為PowP1,關於第一實施例的DiC、DiP1、DiC/DiP1、PowC、PowP1、|PowC – PowP1|的數值請參見表一。
請同時參照表二以及第5圖,表二列出第一實施例的多焦點隱形眼鏡的半徑及其所對應的屈光度,第5圖為第一實施例的多焦點隱形眼鏡的半徑與屈光度的關係圖(負值僅示意為相反方向半徑距離),由表二以及第5圖可知,中心區的屈光度固定,第一環形區的屈光度與中心區的屈光度不同,具體來說,第一環形區的屈光度大於中心區的屈光度,且第一環形區的屈光度隨遠離中心區而遞增。
第一實施例多焦點隱形眼鏡的材質為水膠,關於製備第一實施例水膠的組成物請參照表三。
由表三可知,藉由添加2-[2-羥基-5-[2-(甲基丙烯醯氧)乙基]苯基]-2H-苯并***,第一實施例的多焦點隱形眼鏡可吸收UV光。As can be seen from Table 3, by adding 2-[2-hydroxy-5-[2-(methacryloxy)ethyl]phenyl]-2H-benzotriazole, the multifocal contact lens of the first embodiment Can absorb UV light.
<第二實施例><Second Embodiment>
第二實施例的多焦點隱形眼鏡,包含中心區、第一環形區以及第二環形區,中心區、第二環形區、第一環形區由中心至周邊依序相連且同圓心,中心區、第二環形區以及第一環形區中至少一者為非球面,關於第二實施例多焦點隱形眼鏡的結構可參照第3圖。The multifocal contact lens of the second embodiment includes a central area, a first annular area and a second annular area. The central area, the second annular area and the first annular area are connected in order from the center to the periphery and are concentric. At least one of the area, the second annular area and the first annular area is aspherical. Refer to Figure 3 for the structure of the multifocal contact lens of the second embodiment.
第二實施例的多焦點隱形眼鏡中,中心區的直徑為DiC,第一環形區的外圓直徑為DiP1,第二環形區的外圓直徑為DiP2,中心區的屈光度為PowC,第一環形區的最大屈光度為PowP1,第二環形區的最大屈光度為PowP2,關於第二實施例的DiC、DiP1、DiP2、DiC/DiP1、DiC/DiP2、PowC、PowP1、PowP2、|PowC – PowP1|的數值請參見表四。
請同時參照表五以及第6圖,表五列出第二實施例的多焦點隱形眼鏡的半徑及其所對應的屈光度,第6圖為第二實施例的多焦點隱形眼鏡的半徑與屈光度的關係圖(負值僅示意為相反方向半徑距離),由表五以及第6圖可知,中心區的屈光度固定,第二環形區的屈光度與中心區的屈光度不同,第一環形區的屈光度與中心區的屈光度不同,具體來說,第二環形區的屈光度大於中心區的屈光度,且第二環形區的屈光度隨遠離中心區而遞增,第一環形區的屈光度大於中心區的屈光度,且第一環形區的屈光度固定。
第二實施例多焦點隱形眼鏡的材質為水膠,關於製備第二實施例水膠的組成物請參照表六A。
由表六A可知,藉由添加2-[2-羥基-5-[2-(甲基丙烯醯氧)乙基]苯基]-2H-苯并***,第二實施例的多焦點隱形眼鏡可吸收UV光。As can be seen from Table 6A, by adding 2-[2-hydroxy-5-[2-(methacryloyloxy)ethyl]phenyl]-2H-benzotriazole, the multifocal invisibility of the second embodiment Glasses absorb UV light.
請參照第7圖,其為第二實施例的多焦點隱形眼鏡與第一比較例的多焦點隱形眼鏡的波長與光穿透率的關係圖,第一比較例與第二實施例的差異在於第一比較例未添加UV吸收成分,具體來說,第一比較例以甲基丙烯酸羥乙酯取代2-[2-羥基-5-[2-(甲基丙烯醯氧)乙基]苯基]-2H-苯并***,由第7圖可推算出第一比較例與第二實施例的多焦點隱形眼鏡對於UV-A(波長範圍316nm~380nm的UV光)的阻隔率,計算方法如下:(1-波長316~380nm的平均穿透率)*100%,以及第一比較例與第二實施例的多焦點隱形眼鏡對於UV-B(波長範圍280nm~315nm的UV光)的阻隔率,計算方法如下:(1-280nm~315nm的平均穿透率)×100%,並將結果列於表六B。
由表六B可知,與第一比較例相較,第二實施例對UV-A的阻隔率以及UV-B的阻隔率均遠大於第一比較例,換言之,第二實施例的多焦點隱形眼鏡可有效吸收UV光,進而可降低視網膜受UV光傷害的機率。As can be seen from Table 6B, compared with the first comparative example, the UV-A blocking rate and UV-B blocking rate of the second embodiment are both much greater than those of the first comparative example. In other words, the multi-focus invisibility of the second embodiment Glasses can effectively absorb UV light, thereby reducing the chance of retinal damage by UV light.
<第三實施例><Third Embodiment>
第三實施例的多焦點隱形眼鏡,包含中心區、第一環形區以及第二環形區,中心區、第二環形區、第一環形區由中心至周邊依序相連且同圓心,中心區、第二環形區以及第一環形區中至少一者為非球面,關於第三實施例多焦點隱形眼鏡的結構可參照第3圖。The multifocal contact lens of the third embodiment includes a central area, a first annular area and a second annular area. The central area, the second annular area and the first annular area are connected in sequence from the center to the periphery and are concentric. At least one of the area, the second annular area and the first annular area is aspherical. Refer to Figure 3 for the structure of the multifocal contact lens of the third embodiment.
第三實施例的多焦點隱形眼鏡中,中心區的直徑為DiC,第一環形區的外圓直徑為DiP1,第二環形區的外圓直徑為DiP2,中心區的屈光度為PowC,第一環形區的最大屈光度為PowP1,第二環形區的最大屈光度為PowP2,關於第三實施例的DiC、DiP1、DiP2、DiC/DiP1、DiC/DiP2、PowC、PowP1、PowP2、|PowC – PowP1|的數值請參見表七。
請同時參照表八以及第8圖,表八列出第三實施例的多焦點隱形眼鏡的半徑及其所對應的屈光度,第8圖為第三實施例的多焦點隱形眼鏡的半徑與屈光度的關係圖(負值僅示意為相反方向半徑距離),由表八以及第8圖可知,中心區的屈光度固定,第二環形區的屈光度與中心區的屈光度不同,第一環形區的屈光度與中心區的屈光度不同,具體來說,第二環形區的屈光度大於中心區的屈光度,且第二環形區的屈光度隨遠離中心區而遞增,第一環形區的屈光度大於中心區的屈光度,且第一環形區的屈光度隨遠離中心區而遞增。
第三實施例多焦點隱形眼鏡的材質為水膠,關於製備第三實施例水膠的組成物請參照表九。
由表九可知,藉由添加2-[2-羥基-5-[2-(甲基丙烯醯氧)乙基]苯基]-2H-苯并***,第三實施例的多焦點隱形眼鏡可吸收UV光。As can be seen from Table 9, by adding 2-[2-hydroxy-5-[2-(methacryloxy)ethyl]phenyl]-2H-benzotriazole, the multifocal contact lens of the third embodiment Can absorb UV light.
<第四實施例><Fourth Embodiment>
第四實施例的多焦點隱形眼鏡,包含中心區以及第一環形區,第一環形區同心環繞中心區,中心區以及第一環形區中至少一者為非球面,關於第四實施例多焦點隱形眼鏡的結構可參照第2圖。The multifocal contact lens of the fourth embodiment includes a central area and a first annular area. The first annular area concentrically surrounds the central area. At least one of the central area and the first annular area is aspherical. Regarding the fourth embodiment, For an example of the structure of a multifocal contact lens, please refer to Figure 2.
第四實施例的多焦點隱形眼鏡中,中心區的直徑為DiC,第一環形區的外圓直徑為DiP1,中心區的屈光度為PowC,第一環形區的最大屈光度為PowP1,關於第四實施例的DiC、DiP1、DiC/DiP1、PowC、PowP1、|PowC – PowP1|的數值請參見表十。
請同時參照表十一以及第9圖,表十一列出第四實施例的多焦點隱形眼鏡的半徑及其所對應的屈光度(負值僅示意為相反方向半徑距離),第9圖為第四實施例的多焦點隱形眼鏡的半徑與屈光度的關係圖,由表十一以及第9圖可知,中心區的屈光度固定,第一環形區的屈光度與中心區的屈光度不同,具體來說,第一環形區的屈光度大於中心區的屈光度,且第一環形區的屈光度隨遠離中心區而遞增。
第四實施例多焦點隱形眼鏡的材質為水膠,關於製備第四實施例水膠的組成物請參照表十二A。
由表十二A可知,藉由添加2-丙烯酸 2-(4-苯甲醯-3-羥基苯氧基)乙基酯,第四實施例的多焦點隱形眼鏡可吸收UV光。As can be seen from Table 12A, by adding 2-(4-benzoyl-3-hydroxyphenoxy)ethyl 2-acrylate, the multifocal contact lens of the fourth embodiment can absorb UV light.
請參照第10圖,其為第四實施例的多焦點隱形眼鏡與第二比較例的多焦點隱形眼鏡的波長與光穿透率的關係圖,第二比較例與第四實施例的差異在於第二比較例未添加UV吸收成分,具體來說,第二比較例以甲基丙烯酸羥乙酯取代2-丙烯酸 2-(4-苯甲醯-3-羥基苯氧基)乙基酯,由第10圖可推算出第二比較例與第四實施例的多焦點隱形眼鏡對於UV-A(波長範圍316nm~380nm的UV光)的阻隔率,計算方法如下:(1-波長316~380nm的平均穿透率)*100%,以及第二比較例與第四實施例的多焦點隱形眼鏡對於UV-B(波長範圍280nm~315nm的UV光)的阻隔率,計算方法如下:(1-280nm~315nm的平均穿透率)×100%,並將結果列於表十二B。
由表十二B可知,與第二比較例相較,第四實施例對UV-A的阻隔率以及UV-B的阻隔率均遠大於第二比較例,換言之,第四實施例的多焦點隱形眼鏡可有效吸收UV光,進而可降低視網膜受UV光傷害的機率。As can be seen from Table 12B, compared with the second comparative example, the UV-A blocking rate and the UV-B blocking rate of the fourth embodiment are both much greater than that of the second comparative example. In other words, the multi-focus of the fourth embodiment Contact lenses can effectively absorb UV light, thereby reducing the chance of retinal damage by UV light.
<第五實施例><Fifth Embodiment>
第五實施例的多焦點隱形眼鏡,包含中心區、第一環形區以及第二環形區,中心區、第二環形區、第一環形區由中心至周邊依序相連且同圓心,中心區、第二環形區以及第一環形區中至少一者為非球面,關於第五實施例多焦點隱形眼鏡的結構可參照第3圖。The multifocal contact lens of the fifth embodiment includes a central area, a first annular area and a second annular area. The central area, the second annular area and the first annular area are connected in order from the center to the periphery and are concentric. At least one of the area, the second annular area and the first annular area is aspherical. Refer to Figure 3 for the structure of the multifocal contact lens of the fifth embodiment.
第五實施例的多焦點隱形眼鏡中,中心區的直徑為DiC,第一環形區的外圓直徑為DiP1,第二環形區的外圓直徑為DiP2,中心區的屈光度為PowC,第一環形區的最大屈光度為PowP1,第二環形區的最大屈光度為PowP2,關於第五實施例的DiC、DiP1、DiP2、DiC/DiP1、DiC/DiP2、PowC、PowP1、PowP2、|PowC – PowP1|的數值請參見表十三。
請同時參照表十四以及第11圖,表十四列出第五實施例的多焦點隱形眼鏡的半徑及其所對應的屈光度,第11圖為第五實施例的多焦點隱形眼鏡的半徑與屈光度的關係圖(負值僅示意為相反方向半徑距離),由表十四以及第11圖可知,中心區的屈光度固定,第二環形區的屈光度與中心區的屈光度不同,第一環形區的屈光度與中心區的屈光度不同,具體來說,第二環形區的屈光度大於中心區的屈光度,且第二環形區的屈光度隨遠離中心區而遞增,第一環形區的屈光度大於中心區的屈光度,且第一環形區的屈光度固定。
第五實施例多焦點隱形眼鏡的材質為水膠,關於製備第五實施例水膠的組成物請參照表十五。
由表十五可知,藉由添加2-丙烯酸 2-(4-苯甲醯-3-羥基苯氧基)乙基酯,第五實施例的多焦點隱形眼鏡可吸收UV光。As can be seen from Table 15, by adding 2-(4-benzoyl-3-hydroxyphenoxy)ethyl 2-acrylate, the multifocal contact lens of the fifth embodiment can absorb UV light.
<第六實施例><Sixth Embodiment>
第六實施例的多焦點隱形眼鏡,包含中心區以及第一環形區,第一環形區同心環繞中心區,中心區以及第一環形區中至少一者為非球面,關於第六實施例多焦點隱形眼鏡的結構可參照第2圖。The multifocal contact lens of the sixth embodiment includes a central area and a first annular area. The first annular area concentrically surrounds the central area. At least one of the central area and the first annular area is aspherical. Regarding the sixth embodiment, For an example of the structure of a multifocal contact lens, please refer to Figure 2.
第六實施例的多焦點隱形眼鏡中,中心區的直徑為DiC,第一環形區的外圓直徑為DiP1,中心區的屈光度為PowC,第一環形區的最大屈光度為PowP1,關於第六實施例的DiC、DiP1、DiC/DiP1、PowC、PowP1、|PowC – PowP1|的數值請參見表十六。
請同時參照表十七以及第12圖,表十七列出第六實施例的多焦點隱形眼鏡的半徑及其所對應的屈光度,第12圖為第六實施例的多焦點隱形眼鏡的半徑與屈光度的關係圖(負值僅示意為相反方向半徑距離),由表十七以及第12圖可知,中心區的屈光度固定,第一環形區的屈光度與中心區的屈光度不同,具體來說,第一環形區的屈光度大於中心區的屈光度,且第一環形區的屈光度隨遠離中心區而遞增。
第六實施例多焦點隱形眼鏡的材質為水膠,關於製備第六實施例水膠的組成物請參照表十八。
由表十八可知,藉由添加2-丙烯酸 2-(4-苯甲醯-3-羥基苯氧基)乙基酯,第六實施例的多焦點隱形眼鏡可吸收UV光。As can be seen from Table 18, by adding 2-(4-benzoyl-3-hydroxyphenoxy)ethyl 2-acrylate, the multifocal contact lens of the sixth embodiment can absorb UV light.
<第七實施例><Seventh Embodiment>
第七實施例的多焦點隱形眼鏡,包含中心區、第一環形區以及第二環形區,中心區、第二環形區、第一環形區由中心至周邊依序相連且同圓心,中心區、第二環形區以及第一環形區中至少一者為非球面,關於第七實施例多焦點隱形眼鏡的結構可參照第3圖。The multifocal contact lens of the seventh embodiment includes a central area, a first annular area and a second annular area. The central area, the second annular area and the first annular area are connected in order from the center to the periphery and are concentric. At least one of the area, the second annular area and the first annular area is an aspherical surface. Refer to Figure 3 for the structure of the multifocal contact lens of the seventh embodiment.
第七實施例的多焦點隱形眼鏡中,中心區的直徑為DiC,第一環形區的外圓直徑為DiP1,第二環形區的外圓直徑為DiP2,中心區的屈光度為PowC,第一環形區的最大屈光度為PowP1,第二環形區的最大屈光度為PowP2,關於第七實施例的DiC、DiP1、DiP2、DiC/DiP1、DiC/DiP2、PowC、PowP1、PowP2、|PowC – PowP1|的數值請參見表十九。
請同時參照表二十以及第13圖,表二十列出第七實施例的多焦點隱形眼鏡的半徑及其所對應的屈光度,第13圖為第七實施例的多焦點隱形眼鏡的半徑與屈光度的關係圖(負值僅示意為相反方向半徑距離),由表二十以及第13圖可知,中心區的屈光度固定,第二環形區的屈光度與中心區的屈光度不同,第一環形區的屈光度與中心區的屈光度不同,具體來說,第二環形區的屈光度大於中心區的屈光度,且第二環形區的屈光度隨遠離中心區而遞增,第一環形區的屈光度大於中心區的屈光度,且第一環形區的屈光度隨遠離中心區而遞增。
第七實施例多焦點隱形眼鏡的材質為水膠,關於製備第七實施例水膠的組成物請參照表二十一A。
由表二十一A可知,藉由添加四苯基二甲基丙烯酸,第七實施例的多焦點隱形眼鏡可吸收藍光。It can be seen from Table 21A that by adding tetraphenyldimethacrylic acid, the multifocal contact lens of the seventh embodiment can absorb blue light.
請參照第14圖,其為第七實施例的多焦點隱形眼鏡與第三比較例的多焦點隱形眼鏡的波長與光穿透率的關係圖,第三比較例與第七實施例的差異在於第三比較例未添加藍光吸收成分,具體來說,第三比較例以甲基丙烯酸羥乙酯取代四苯基二甲基丙烯酸,由第14圖可推算出第三比較例與第七實施例的多焦點隱形眼鏡對於藍光(波長範圍380nm~495nm)的阻隔率,計算方法如下:(1-波長380~495nm的平均穿透率)*100%,並將結果列於表二十一B。
由表二十一B可知,與第三比較例相較,第七實施例對藍光的阻隔率遠大於第三比較例,換言之,第七實施例的多焦點隱形眼鏡可有效吸收藍光,進而可降低視網膜受藍光傷害的機率。It can be seen from Table 21B that compared with the third comparative example, the blue light blocking rate of the seventh embodiment is much greater than that of the third comparative example. In other words, the multifocal contact lens of the seventh embodiment can effectively absorb blue light, and thus can Reduces the chance of retinal damage from blue light.
<第八實施例><Eighth Embodiment>
第八實施例的多焦點隱形眼鏡,包含中心區以及第一環形區,第一環形區同心環繞中心區,中心區以及第一環形區中至少一者為非球面,關於第八實施例多焦點隱形眼鏡的結構可參照第2圖。The multifocal contact lens of the eighth embodiment includes a central area and a first annular area. The first annular area concentrically surrounds the central area. At least one of the central area and the first annular area is aspherical. Regarding the eighth embodiment, For an example of the structure of a multifocal contact lens, please refer to Figure 2.
第八實施例的多焦點隱形眼鏡中,中心區的直徑為DiC,第一環形區的外圓直徑為DiP1,中心區的屈光度為PowC,第一環形區的最大屈光度為PowP1,關於第八實施例的DiC、DiP1、DiC/DiP1、PowC、PowP1、|PowC – PowP1|的數值請參見表二十二。
請同時參照表二十三以及第15圖,表二十三列出第八實施例的多焦點隱形眼鏡的半徑及其所對應的屈光度,第15圖為第八實施例的多焦點隱形眼鏡的半徑與屈光度的關係圖(負值僅示意為相反方向半徑距離),由表二十三以及第15圖可知,中心區的屈光度固定,第一環形區的屈光度與中心區的屈光度不同,具體來說,第一環形區的屈光度大於中心區的屈光度,且第一環形區的屈光度隨遠離中心區而遞增。
第八實施例多焦點隱形眼鏡的材質為水膠,關於製備第八實施例水膠的組成物請參照表二十四。
由表二十四可知,藉由添加四苯基二甲基丙烯酸,第八實施例的多焦點隱形眼鏡可吸收藍光。It can be seen from Table 24 that by adding tetraphenyldimethacrylic acid, the multifocal contact lens of the eighth embodiment can absorb blue light.
<第九實施例><Ninth Embodiment>
第九實施例的多焦點隱形眼鏡,包含中心區、第一環形區以及第二環形區,中心區、第二環形區、第一環形區由中心至周邊依序相連且同圓心,中心區、第二環形區以及第一環形區中至少一者為非球面,關於第九實施例多焦點隱形眼鏡的結構可參照第3圖。The multifocal contact lens of the ninth embodiment includes a central area, a first annular area and a second annular area. The central area, the second annular area and the first annular area are connected in order from the center to the periphery and are concentric. At least one of the area, the second annular area and the first annular area is an aspheric surface. For the structure of the multifocal contact lens of the ninth embodiment, please refer to Figure 3 .
第九實施例的多焦點隱形眼鏡中,中心區的直徑為DiC,第一環形區的外圓直徑為DiP1,第二環形區的外圓直徑為DiP2,中心區的屈光度為PowC,第一環形區的最大屈光度為PowP1,第二環形區的最大屈光度為PowP2,關於第九實施例的DiC、DiP1、DiP2、DiC/DiP1、DiC/DiP2、PowC、PowP1、PowP2、|PowC – PowP1|的數值請參見表二十五。
請同時參照表二十六以及第16圖,表二十六列出第九實施例的多焦點隱形眼鏡的半徑及其所對應的屈光度,第16圖為第九實施例的多焦點隱形眼鏡的半徑與屈光度的關係圖(負值僅示意為相反方向半徑距離),由表二十六以及第16圖可知,中心區的屈光度固定,第二環形區的屈光度與中心區的屈光度不同,第一環形區的屈光度與中心區的屈光度不同,具體來說,第二環形區的屈光度大於中心區的屈光度,且第二環形區的屈光度隨遠離中心區而遞增,第一環形區的屈光度大於中心區的屈光度,且第一環形區的屈光度隨遠離中心區而遞增。
第九實施例多焦點隱形眼鏡的材質為水膠,關於製備第九實施例水膠的組成物請參照表二十七。
由表二十七可知,藉由添加四苯基二甲基丙烯酸,第九實施例的多焦點隱形眼鏡可吸收藍光。It can be seen from Table 27 that by adding tetraphenyldimethacrylic acid, the multifocal contact lens of the ninth embodiment can absorb blue light.
<第十實施例><Tenth Embodiment>
第十實施例的多焦點隱形眼鏡,包含中心區以及第一環形區,第一環形區同心環繞中心區,中心區以及第一環形區中至少一者為非球面,關於第十實施例多焦點隱形眼鏡的結構可參照第2圖。The multifocal contact lens of the tenth embodiment includes a central area and a first annular area, the first annular area concentrically surrounds the central area, and at least one of the central area and the first annular area is aspherical. Regarding the tenth embodiment For an example of the structure of a multifocal contact lens, please refer to Figure 2.
第十實施例的多焦點隱形眼鏡中,中心區的直徑為DiC,第一環形區的外圓直徑為DiP1,中心區的屈光度為PowC,第一環形區的最大屈光度為PowP1,關於第十實施例的DiC、DiP1、DiC/DiP1、PowC、PowP1、|PowC – PowP1|的數值請參見表二十八。
請同時參照表二十九以及第17圖,表二十九列出第十實施例的多焦點隱形眼鏡的半徑及其所對應的屈光度,第17圖為第十實施例的多焦點隱形眼鏡的半徑與屈光度的關係圖(負值僅示意為相反方向半徑距離),由表二十九以及第17圖可知,中心區的屈光度固定,第一環形區的屈光度與中心區的屈光度不同,具體來說,第一環形區的屈光度大於中心區的屈光度,且第一環形區的屈光度隨遠離中心區而遞增。
第十實施例多焦點隱形眼鏡的材質為矽水膠,關於製備第十實施例矽水膠的組成物請參照表三十。
由表三十可知,藉由添加2-丙烯酸 2-(4-苯甲醯-3-羥基苯氧基)乙基酯,第十實施例的多焦點隱形眼鏡可吸收UV光。As can be seen from Table 30, by adding 2-(4-benzoyl-3-hydroxyphenoxy)ethyl 2-acrylate, the multifocal contact lens of the tenth embodiment can absorb UV light.
<第十一實施例><Eleventh Embodiment>
第十一實施例的多焦點隱形眼鏡,包含中心區、第一環形區以及第二環形區,中心區、第二環形區、第一環形區由中心至周邊依序相連且同圓心,中心區、第二環形區以及第一環形區中至少一者為非球面,關於第十一實施例多焦點隱形眼鏡的結構可參照第3圖。The multifocal contact lens of the eleventh embodiment includes a central area, a first annular area and a second annular area. The central area, the second annular area and the first annular area are connected in order from the center to the periphery and are concentric. At least one of the central area, the second annular area and the first annular area is aspherical. Refer to Figure 3 for the structure of the multifocal contact lens of the eleventh embodiment.
第十一實施例的多焦點隱形眼鏡中,中心區的直徑為DiC,第一環形區的外圓直徑為DiP1,第二環形區的外圓直徑為DiP2,中心區的屈光度為PowC,第一環形區的最大屈光度為PowP1,第二環形區的最大屈光度為PowP2,關於第十一實施例的DiC、DiP1、DiP2、DiC/DiP1、DiC/DiP2、PowC、PowP1、PowP2、|PowC – PowP1|的數值請參見表三十一。
請同時參照表三十二以及第18圖,表三十二列出第十一實施例的多焦點隱形眼鏡的半徑及其所對應的屈光度,第18圖為第十一實施例的多焦點隱形眼鏡的半徑與屈光度的關係圖(負值僅示意為相反方向半徑距離),由表三十二以及第18圖可知,中心區的屈光度固定,第二環形區的屈光度與中心區的屈光度不同,第一環形區的屈光度與中心區的屈光度不同,具體來說,第二環形區的屈光度大於中心區的屈光度,且第二環形區的屈光度隨遠離中心區而遞增,第一環形區的屈光度大於中心區的屈光度,且第一環形區的屈光度隨遠離中心區而遞增。
第十一實施例多焦點隱形眼鏡的材質為矽水膠,關於製備第十一實施例矽水膠的組成物請參照表三十三A。
由表三十三A可知,藉由添加2-丙烯酸 2-(4-苯甲醯-3-羥基苯氧基)乙基酯,第十一實施例的多焦點隱形眼鏡可吸收UV光。It can be seen from Table 33A that by adding 2-(4-benzoyl-3-hydroxyphenoxy)ethyl 2-acrylate, the multifocal contact lens of the eleventh embodiment can absorb UV light.
請參照第19圖,其為第十一實施例的多焦點隱形眼鏡與第四比較例的多焦點隱形眼鏡的波長與光穿透率的關係圖,第四比較例與第十一實施例的差異在於第四比較例未添加UV吸收成分,具體來說,第四比較例以甲基丙烯酸羥乙酯取代2-丙烯酸 2-(4-苯甲醯-3-羥基苯氧基)乙基酯,由第19圖可推算出第四比較例與第十一實施例的多焦點隱形眼鏡對於UV-A(波長範圍316nm~380nm的UV光)的阻隔率,計算方法如下:(1-波長316~380nm的平均穿透率)*100%,以及第四比較例與第十一實施例的多焦點隱形眼鏡對於UV-B(波長範圍280nm~315nm的UV光)的阻隔率,計算方法如下:(1-280nm~315nm的平均穿透率)×100%,並將結果列於表三十三B。
由表三十三B可知,與第四比較例相較,第十一實施例對UV-A的阻隔率以及UV-B的阻隔率均遠大於第四比較例,換言之,第十一實施例的多焦點隱形眼鏡可有效吸收UV光,進而可降低視網膜受UV光傷害的機率。It can be seen from Table 33B that compared with the fourth comparative example, the UV-A blocking rate and the UV-B blocking rate of the eleventh embodiment are both much greater than the fourth comparative example. In other words, the eleventh embodiment Multifocal contact lenses can effectively absorb UV light, thereby reducing the chance of retinal damage by UV light.
<第十二實施例><Twelfth Embodiment>
第十二實施例的多焦點隱形眼鏡,包含中心區、第一環形區、第二環形區以及第三環形區,中心區、第三環形區、第二環形區、第一環形區由中心至周邊依序相連且同圓心,中心區、第三環形區、第二環形區以及第一環形區中至少一者為非球面,關於第十二實施例多焦點隱形眼鏡的結構可參照第4圖。The multifocal contact lens of the twelfth embodiment includes a central area, a first annular area, a second annular area and a third annular area. The central area, the third annular area, the second annular area and the first annular area are composed of The center is connected in sequence from the center to the periphery and is concentric with the center of the circle. At least one of the central area, the third annular area, the second annular area and the first annular area is aspherical. Regarding the structure of the multifocal contact lens of the twelfth embodiment, please refer to Picture 4.
第十二實施例的多焦點隱形眼鏡中,中心區的直徑為DiC,第一環形區的外圓直徑為DiP1,第二環形區的外圓直徑為DiP2,第三環形區的外圓直徑為DiP3,中心區的屈光度為PowC,第一環形區的最大屈光度為PowP1,第二環形區的最大屈光度為PowP2,第三環形區的最大屈光度為PowP3,關於第十二實施例的DiC、DiP1、DiP2、DiP3、DiC/DiP1、DiC/DiP2、PowC、PowP1、PowP2、PowP3、|PowC – PowP1|的數值請參見表三十四。
請同時參照表三十五以及第20圖,表三十五列出第十二實施例的多焦點隱形眼鏡的半徑及其所對應的屈光度,第20圖為第十二實施例的多焦點隱形眼鏡的半徑與屈光度的關係圖(負值僅示意為相反方向半徑距離),由表三十五以及第20圖可知,中心區的屈光度固定,第三環形區的屈光度與中心區的屈光度不同,第二環形區的屈光度與中心區的屈光度不同,第一環形區的屈光度與中心區的屈光度不同,具體來說,第三環形區的屈光度大於中心區的屈光度,且第三環形區的屈光度隨遠離中心區而遞增,第二環形區的屈光度大於中心區的屈光度,且第二環形區的屈光度隨遠離中心區而遞增,第一環形區的屈光度大於中心區的屈光度,且第一環形區的屈光度固定。
第十二實施例多焦點隱形眼鏡的材質為矽水膠,關於製備第十二實施例水膠的組成物請參照表三十六A。
由表三十六A可知,藉由添加四苯基二甲基丙烯酸,第十二實施例的多焦點隱形眼鏡可吸收藍光。It can be seen from Table 36A that by adding tetraphenyldimethacrylic acid, the multifocal contact lens of the twelfth embodiment can absorb blue light.
請參照第21圖,其為第十二實施例的多焦點隱形眼鏡與第五比較例的多焦點隱形眼鏡的波長與光穿透率的關係圖,第五比較例與第十二實施例的差異在於第五比較例未添加藍光吸收成分,具體來說,第五比較例以甲基丙烯酸羥乙酯取代四苯基二甲基丙烯酸,由第21圖可推算出第五比較例與第十二實施例的多焦點隱形眼鏡對於藍光(波長範圍380nm~495nm)的阻隔率,計算方法如下:(1-波長380~495nm的平均穿透率)*100%,並將結果列於表三十六B。
由表三十六B可知,與第五比較例相較,第十二實施例對藍光的阻隔率遠大於第五比較例,換言之,第十二實施例的多焦點隱形眼鏡可有效吸收藍光,進而可降低視網膜受藍光傷害的機率。As can be seen from Table 36B, compared with the fifth comparative example, the blue light blocking rate of the twelfth embodiment is much greater than that of the fifth comparative example. In other words, the multifocal contact lens of the twelfth embodiment can effectively absorb blue light. This in turn reduces the chance of retinal damage from blue light.
本發明中多焦點隱形眼鏡上的非球面意指正表面或背表面於過中心剖面下的曲面形狀,其中正表面指遠離眼球角膜的表面,背表面指靠近眼球角膜的表面。In the present invention, the aspherical surface on the multifocal contact lens refers to the curved surface shape of the front surface or the back surface under the cross-center section, where the front surface refers to the surface far away from the cornea of the eyeball, and the back surface refers to the surface close to the cornea of the eyeball.
本發明中的屈光度以D值表示,當校正近視的鏡片屈光度為負值,校正遠視的鏡片屈光度為正值。The diopter in the present invention is expressed by D value. When the diopter of the lens for correcting myopia is a negative value, the diopter of the lens for correcting hyperopia is a positive value.
本發明中的睫狀肌麻痺劑包含但不限於阿托品(Atropine;(3-endo)-8-Methyl-8-azabicyclo[3.2.1]oct-3-yl tropate)、托吡卡胺(Tropicamide;N-Ethyl-3-hydroxy-2-phenyl-N-(4-pyridinylmethyl)propanamide)、環戊醇胺酯(Cyclopentolate;2-(Dimethylamino)ethyl (1-hydroxycyclopentyl)(phenyl)acetate)、后馬托品(Homatropine;(3-endo)-8-Methyl-8-azabicyclo[3.2.1]oct-3-yl hydroxy(phenyl)acetate)、東莨菪鹼(Scopolamine ;(1R,2R,4S,5S,7s)-9-Methyl-3-oxa-9-azatricyclo[3.3.1.0 2,4]non-7-yl(2S)-3-hydroxy-2-phenylpropanoate)與尤卡托品(Eucatropine;1,2,2,6-Tetramethyl-4-piperidinyl hydroxy(phenyl)acetate)及前述物質的鹽類。睫狀肌麻痺劑又稱為作散瞳劑,並屬於副交感神經阻斷劑,亦即為一種非選擇性的M型蕈毒鹼受器阻斷藥,其可藉由阻斷蕈毒鹼受器而使控制瞳孔的睫狀肌麻痺與鬆弛,進而使得瞳孔放大。 Cycloplegic agents in the present invention include, but are not limited to, atropine (Atropine; (3-endo)-8-Methyl-8-azabicyclo[3.2.1]oct-3-yl tropate), tropicamide; N-Ethyl-3-hydroxy-2-phenyl-N-(4-pyridinylmethyl)propanamide), Cyclopentolate; 2-(Dimethylamino)ethyl (1-hydroxycyclopentyl)(phenyl)acetate), houmatolate Product (Homatropine; (3-endo)-8-Methyl-8-azabicyclo[3.2.1]oct-3-yl hydroxy(phenyl)acetate), Scopolamine (Scopolamine; (1R, 2R, 4S, 5S, 7s)- 9-Methyl-3-oxa-9-azatricyclo[3.3.1.0 2,4 ]non-7-yl(2S)-3-hydroxy-2-phenylpropanoate) and Eucatropine (Eucatropine; 1,2,2, 6-Tetramethyl-4-piperidinyl hydroxy(phenyl)acetate) and salts of the aforementioned substances. Cycloplegic agents are also called mydriatic agents and are parasympathetic blockers, which are non-selective M-type muscarinic receptor blockers. They can block muscarinic receptors by The device paralyzes and relaxes the cycloplegic muscle that controls the pupil, thereby causing the pupil to dilate.
雖然本發明已以實施方式揭露如上,然其並非用以限定本發明,任何熟習此技藝者,在不脫離本發明的精神和範圍內,當可作各種的更動與潤飾,因此本發明的保護範圍當視後附的申請專利範圍所界定者為準。Although the present invention has been disclosed in the above embodiments, it is not intended to limit the present invention. Anyone skilled in the art can make various modifications and modifications without departing from the spirit and scope of the present invention. Therefore, the protection of the present invention is The scope shall be determined by the appended patent application scope.
100:隱形眼鏡產品 110,210,310:多焦點隱形眼鏡 111,211,311:中心區 112,212,312:第一環形區 120:緩衝溶液 213,313:第二環形區 314:第三環形區 DiC:中心區的直徑 DiP1:第一環形區的外圓直徑 DiP2:第二環形區的外圓直徑 DiP3:第三環形區的外圓直徑 PowC:中心區的屈光度 PowP1:第一環形區的最大屈光度 PowP2:第二環形區的最大屈光度 PowP3:第三環形區的最大屈光度 100:Contact lens products 110,210,310:Multifocal contact lenses 111,211,311:Central area 112,212,312: First ring area 120: Buffer solution 213,313: Second ring area 314:The third ring area DiC: diameter of central area DiP1: outer diameter of the first annular zone DiP2: outer diameter of the second annular zone DiP3: outer diameter of the third annular zone PowC: diopter in central area PowP1: Maximum diopter of the first annular zone PowP2: Maximum diopter of the second annular zone PowP3: Maximum diopter of the third annular zone
為讓本發明的上述和其他目的、特徵、優點與實施例能更明顯易懂,所附圖式的說明如下: 第1圖繪示依照本發明一實施方式的一種隱形眼鏡產品的示意圖; 第2圖繪示第1圖中多焦點隱形眼鏡的平面示意圖; 第3圖繪示依照本發明另一實施方式的一種多焦點隱形眼鏡的平面示意圖; 第4圖繪示依照本發明又一實施方式的一種多焦點隱形眼鏡的平面示意圖; 第5圖為第一實施例的多焦點隱形眼鏡的半徑與屈光度的關係圖; 第6圖為第二實施例的多焦點隱形眼鏡的半徑與屈光度的關係圖; 第7圖為第二實施例的多焦點隱形眼鏡與第一比較例的多焦點隱形眼鏡的波長與光穿透率的關係圖; 第8圖為第三實施例的多焦點隱形眼鏡的半徑與屈光度的關係圖; 第9圖為第四實施例的多焦點隱形眼鏡的半徑與屈光度的關係圖; 第10圖為第四實施例的多焦點隱形眼鏡與第二比較例的多焦點隱形眼鏡的波長與光穿透率的關係圖; 第11圖為第五實施例的多焦點隱形眼鏡的半徑與屈光度的關係圖; 第12圖為第六實施例的多焦點隱形眼鏡的半徑與屈光度的關係圖; 第13圖為第七實施例的多焦點隱形眼鏡的半徑與屈光度的關係圖; 第14圖為第七實施例的多焦點隱形眼鏡與第三比較例的多焦點隱形眼鏡的波長與光穿透率的關係圖; 第15圖為第八實施例的多焦點隱形眼鏡的半徑與屈光度的關係圖; 第16圖為第九實施例的多焦點隱形眼鏡的半徑與屈光度的關係圖; 第17圖為第十實施例的多焦點隱形眼鏡的半徑與屈光度的關係圖; 第18圖為第十一實施例的多焦點隱形眼鏡的半徑與屈光度的關係圖; 第19圖為第十一實施例的多焦點隱形眼鏡與第四比較例的多焦點隱形眼鏡的波長與光穿透率的關係圖; 第20圖為第十二實施例的多焦點隱形眼鏡的半徑與屈光度的關係圖;以及 第21圖為第十二實施例的多焦點隱形眼鏡與第五比較例的多焦點隱形眼鏡的波長與光穿透率的關係圖。 In order to make the above and other objects, features, advantages and embodiments of the present invention more apparent and understandable, the accompanying drawings are described as follows: Figure 1 is a schematic diagram of a contact lens product according to an embodiment of the present invention; Figure 2 shows a schematic plan view of the multifocal contact lens in Figure 1; Figure 3 is a schematic plan view of a multifocal contact lens according to another embodiment of the present invention; Figure 4 is a schematic plan view of a multifocal contact lens according to another embodiment of the present invention; Figure 5 is a diagram showing the relationship between the radius and diopter of the multifocal contact lens of the first embodiment; Figure 6 is a diagram showing the relationship between the radius and diopter of the multifocal contact lens of the second embodiment; Figure 7 is a diagram showing the relationship between wavelength and light transmittance of the multifocal contact lens of the second embodiment and the multifocal contact lens of the first comparative example; Figure 8 is a diagram showing the relationship between the radius and diopter of the multifocal contact lens of the third embodiment; Figure 9 is a diagram showing the relationship between the radius and diopter of the multifocal contact lens of the fourth embodiment; Figure 10 is a diagram showing the relationship between wavelength and light transmittance of the multifocal contact lens of the fourth embodiment and the multifocal contact lens of the second comparative example; Figure 11 is a diagram showing the relationship between the radius and diopter of the multifocal contact lens of the fifth embodiment; Figure 12 is a diagram showing the relationship between the radius and diopter of the multifocal contact lens of the sixth embodiment; Figure 13 is a diagram showing the relationship between the radius and diopter of the multifocal contact lens of the seventh embodiment; Figure 14 is a diagram showing the relationship between wavelength and light transmittance of the multifocal contact lens of the seventh embodiment and the multifocal contact lens of the third comparative example; Figure 15 is a diagram showing the relationship between the radius and diopter of the multifocal contact lens of the eighth embodiment; Figure 16 is a diagram showing the relationship between the radius and diopter of the multifocal contact lens of the ninth embodiment; Figure 17 is a diagram showing the relationship between the radius and the diopter of the multifocal contact lens of the tenth embodiment; Figure 18 is a diagram showing the relationship between the radius and diopter of the multifocal contact lens according to the eleventh embodiment; Figure 19 is a graph showing the relationship between wavelength and light transmittance of the multifocal contact lens of the eleventh embodiment and the multifocal contact lens of the fourth comparative example; Figure 20 is a graph showing the relationship between the radius and diopter of the multifocal contact lens of the twelfth embodiment; and Figure 21 is a graph showing the relationship between wavelength and light transmittance of the multifocal contact lens of the twelfth embodiment and the multifocal contact lens of the fifth comparative example.
100:隱形眼鏡產品 100:Contact lens products
110:多焦點隱形眼鏡 110:Multifocal contact lenses
120:緩衝溶液 120: Buffer solution
Claims (11)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW104130460 | 2015-09-15 | ||
TW104130460 | 2015-09-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW202403401A true TW202403401A (en) | 2024-01-16 |
Family
ID=58774587
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW111134338A TWI822320B (en) | 2015-09-15 | 2015-10-29 | Contact lens product |
TW109124138A TWI741684B (en) | 2015-09-15 | 2015-10-29 | Contact lens product |
TW106113509A TWI652521B (en) | 2015-09-15 | 2015-10-29 | Contact lens product |
TW112138175A TW202403401A (en) | 2015-09-15 | 2015-10-29 | Contact lens product |
TW110131368A TWI780873B (en) | 2015-09-15 | 2015-10-29 | Contact lens product |
TW104135628A TWI587033B (en) | 2015-09-15 | 2015-10-29 | Contact lens product |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW111134338A TWI822320B (en) | 2015-09-15 | 2015-10-29 | Contact lens product |
TW109124138A TWI741684B (en) | 2015-09-15 | 2015-10-29 | Contact lens product |
TW106113509A TWI652521B (en) | 2015-09-15 | 2015-10-29 | Contact lens product |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW110131368A TWI780873B (en) | 2015-09-15 | 2015-10-29 | Contact lens product |
TW104135628A TWI587033B (en) | 2015-09-15 | 2015-10-29 | Contact lens product |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP2019211789A (en) |
TW (6) | TWI822320B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI738294B (en) * | 2019-03-28 | 2021-09-01 | 星歐光學股份有限公司 | Contact lens and contact lens product |
TWI780838B (en) * | 2019-03-28 | 2022-10-11 | 星歐光學股份有限公司 | Contact lens and contact lens product |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL117935A0 (en) * | 1995-05-04 | 1996-08-04 | Johnson & Johnson Vision Prod | Multifocal ophthalmic lens |
BRPI0712422A2 (en) * | 2006-06-08 | 2012-07-03 | Vision Crc Ltd | means for controlling the progression of myopia. |
US8470906B2 (en) * | 2008-09-30 | 2013-06-25 | Johnson & Johnson Vision Care, Inc. | Ionic silicone hydrogels having improved hydrolytic stability |
US8632187B1 (en) * | 2009-04-27 | 2014-01-21 | Dakota Sciences, Inc. | Progressive multifocal rigid gas permeable contact lens |
US20120113386A1 (en) * | 2009-05-04 | 2012-05-10 | Coopervision International Holding Company, Lp | Small Optic Zone Contact Lenses And Methods |
KR20120035159A (en) * | 2009-10-22 | 2012-04-13 | 쿠퍼비젼 인터내셔날 홀딩 캄파니, 엘피 | Contact lens sets and methods to prevent or slow progression of myopia or hyperopia |
WO2014210186A2 (en) * | 2013-06-26 | 2014-12-31 | Nexisvision, Inc. | Contact lenses for refractive correction |
TWI434826B (en) | 2011-04-28 | 2014-04-21 | Largan Medical Co Ltd | Composition of contact lens for uv resistant |
CN102382237B (en) * | 2011-08-12 | 2013-07-10 | 北京自然美光学有限公司 | Radiation-proof light-filtering contact lens and production method thereof |
TWI516830B (en) | 2012-05-07 | 2016-01-11 | 星歐光學股份有限公司 | Contact lens for myopia control |
US8915590B2 (en) * | 2012-05-18 | 2014-12-23 | Johnson & Johnson Vision Care, Inc. | Contact lens with halo effect |
US9827250B2 (en) * | 2012-07-31 | 2017-11-28 | Johnson & Johnson Vision Care, Inc. | Lens incorporating myopia control optics and muscarinic agents |
US9987808B2 (en) * | 2013-11-22 | 2018-06-05 | Johnson & Johnson Vision Care, Inc. | Methods for formation of an ophthalmic lens with an insert utilizing voxel-based lithography techniques |
CN106526888B (en) * | 2015-09-15 | 2019-08-06 | 星欧光学股份有限公司 | contact lens product |
-
2015
- 2015-10-29 TW TW111134338A patent/TWI822320B/en active
- 2015-10-29 TW TW109124138A patent/TWI741684B/en active
- 2015-10-29 TW TW106113509A patent/TWI652521B/en active
- 2015-10-29 TW TW112138175A patent/TW202403401A/en unknown
- 2015-10-29 TW TW110131368A patent/TWI780873B/en active
- 2015-10-29 TW TW104135628A patent/TWI587033B/en active
-
2019
- 2019-09-04 JP JP2019161137A patent/JP2019211789A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
TWI780873B (en) | 2022-10-11 |
TWI587033B (en) | 2017-06-11 |
TWI741684B (en) | 2021-10-01 |
TW201710748A (en) | 2017-03-16 |
TW202040224A (en) | 2020-11-01 |
TW202144868A (en) | 2021-12-01 |
TW201730631A (en) | 2017-09-01 |
TW202301000A (en) | 2023-01-01 |
TWI652521B (en) | 2019-03-01 |
JP2019211789A (en) | 2019-12-12 |
TWI822320B (en) | 2023-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11467425B2 (en) | Contact lens product | |
US10578889B2 (en) | Contact lens product | |
US10371964B2 (en) | Contact lens product | |
TWI639028B (en) | Contact lens product | |
US11782294B2 (en) | Multifocal contact lens and contact lens product | |
TWI822320B (en) | Contact lens product | |
TWI702438B (en) | Contact lens product | |
US20230393417A1 (en) | Multifocal contact lens and contact lens product |